Document:

EX-4.2

 Exhibit 4.2 

ADURO BIOTECH, INC. 
 AMENDED AND
RESTATED INVESTOR RIGHTS AGREEMENT 
 December 19, 2014 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
			
	1.	  	Certain Definitions	  	 	1	  
			
	2.	  	Registration Rights	  	 	6	  
				
		  	2.1	  	Required Registrations	  	 	6	  
				
		  	2.2	  	Incidental Registration	  	 	8	  
				
		  	2.3	  	Registration Procedures	  	 	9	  
				
		  	2.4	  	Allocation of Expenses	  	 	11	  
				
		  	2.5	  	Indemnification and Contribution	  	 	11	  
				
		  	2.6	  	Other Matters with Respect to Underwritten Offerings	  	 	14	  
				
		  	2.7	  	Information by Holder	  	 	14	  
				
		  	2.8	  	“Lock-Up” Agreement; Confidentiality of Notices	  	 	14	  
				
		  	2.9	  	Limitations on Subsequent Registration Rights	  	 	15	  
				
		  	2.10	  	Rule 144 Requirements	  	 	16	  
				
		  	2.11	  	Registration in Other Jurisdictions	  	 	16	  
				
		  	2.12	  	Termination	  	 	16	  
			
	3.	  	Right of First Refusal	  	 	17	  
				
		  	3.1	  	Rights of Purchasers to Acquire Offered Securities	  	 	17	  
				
		  	3.2	  	Waiver	  	 	19	  
				
		  	3.3	  	Termination	  	 	20	  
			
	4.	  	Covenants	  	 	20	  
				
		  	4.1	  	Negative Covenants	  	 	20	  
				
		  	4.2	  	Affirmative Covenants	  	 	20	  
				
		  	4.3	  	Inspection and Observation	  	 	22	  
				
		  	4.4	  	Financial Statements and Other Information	  	 	22	  
				
		  	4.5	  	Material Changes and Litigation	  	 	23	  
				
		  	4.6	  	Key Man Insurance	  	 	23	  
				
		  	4.7	  	Agreements with Employees; Options	  	 	23	  
				
		  	4.8	  	Board of Directors	  	 	24	  
				
		  	4.9	  	Related Party Transactions	  	 	24	  
				
		  	4.10	  	Reservation of Common Stock	  	 	25	  
				
		  	4.11	  	International Investment and Trade in Services Survey Act	  	 	25	  

  
 -i- 

 TABLE OF CONTENTS 

(continued) 

									
	 	  	 	  	 	  	Page	 
				
		  	4.12	  	JJDC Observer Right	  	 	25	  
				
		  	4.13	  	Pay-to-Play Protection	  	 	25	  
				
		  	4.14	  	Publicity	  	 	26	  
				
		  	4.15	  	No Promotion	  	 	26	  
				
		  	4.16	  	Termination of Covenants	  	 	26	  
			
	5.	  	Confidentiality	  	 	26	  
			
	6.	  	Transfers of Rights; Calculation of Share Numbers	  	 	27	  
				
		  	6.1	  	Transfer of Rights	  	 	27	  
				
		  	6.2	  	Calculation of Share Numbers	  	 	27	  
			
	7.	  	General	  	 	27	  
				
		  	7.1	  	Severability	  	 	27	  
				
		  	7.2	  	Specific Performance	  	 	27	  
				
		  	7.3	  	Governing Law	  	 	28	  
				
		  	7.4	  	Notices	  	 	28	  
				
		  	7.5	  	Complete Agreement	  	 	28	  
				
		  	7.6	  	Amendments and Waivers	  	 	28	  
				
		  	7.7	  	Pronouns	  	 	29	  
				
		  	7.8	  	Counterparts; Facsimile Signatures	  	 	29	  
				
		  	7.9	  	Section Headings and References	  	 	29	  
				
		  	7.10	  	Additional Purchasers	  	 	29	  
				
		  	7.11	  	Massachusetts Business Trust	  	 	30	  
				
		  	7.12	  	Amendment and Restatement of Prior Agreement	  	 	30	  

  
 -ii- 

 ADURO BIOTECH, INC. 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

This Agreement dated as of December 19, 2014 is entered into by and among Aduro Biotech, Inc., a Delaware corporation (the
“Company”), and the individuals and entities listed on Exhibit A attached hereto (the “Purchasers”).  

Recitals 
 WHEREAS,
the Company and certain of the Purchasers have entered into a Series D Preferred Stock Purchase Agreement of even date herewith (as the same may be amended from time to time, the “Purchase Agreement”), pursuant to which such
Purchasers are purchasing shares of Series D Preferred Stock, $0.0001 par value per share (the “Series D Preferred”), of the Company; 

WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement; 

WHEREAS, the Company and certain of the Purchasers (the “Prior Parties”) previously entered into that certain Amended
and Restated Investor Rights Agreement dated May 30, 2014 (the “Prior Investor Rights Agreement”);  
 WHEREAS,
the Company and the Purchasers desire to provide for certain arrangements with respect to (i) the registration of shares of capital stock of the Company under the Securities Act (as defined below), (ii) certain Purchasers’ right of
first refusal with respect to certain issuances of securities of the Company, and (iii) certain covenants of the Company; and 

WHEREAS, the Company and the Prior Parties desire to amend and restate the Prior Investor Rights Agreement in its entirety pursuant to the
terms hereof. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, the parties hereto agree
as follows: 
 1. Certain Definitions. 

As used in this Agreement, the following terms shall have the following respective meanings: 

“Affiliated Party” means, with respect to any Purchaser, shall mean, with respect to any Purchaser, (a) any person or
entity which, directly or indirectly, controls, is controlled by or is under common control with such Purchaser, including, without limitation, any general partner, officer or director of such Purchaser, (b) any venture capital fund now or
hereafter existing which is controlled by one or more general partners of, or shares the same management company as, such Purchaser, (c) any registered investment company that shares the same investment advisor, and (d) a child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law, including any trust for the benefit of the Purchaser or any of the foregoing persons. 

 “Available Undersubscription Amount” means the difference between the total of
all of the Basic Amounts available for purchase by Qualified Purchasers pursuant to Section 3.1 and the Basic Amounts subscribed for pursuant to Section 3.1. 

“Basic Amount” means, with respect to a Qualified Purchaser, its pro rata portion of the Offered Securities determined by
multiplying the number of Offered Securities by a fraction, the numerator of which is the aggregate number of shares of Common Stock that are then held by such Qualified Purchaser or that are issuable upon conversion of all Shares (including Shares
held pursuant to Series B Warrants) and other convertible securities and convertible notes of the Company then held by such Qualified Purchaser and the denominator of which is the total number of shares of Common Stock then outstanding (giving
effect to the conversion into Common Stock of all outstanding shares of convertible Preferred Stock). 
 “Charter” means
the Amended and Restated Certificate of Incorporation of the Company, as in effect as of the date hereof, as the same may be amended and restated from time to time. 

“Code” means the Internal Revenue Code of 1986, as amended. 

“Commission” means the Securities and Exchange Commission or any other federal agency at the time administering the
Securities Act. 
 “Common Stock” means the common stock, $0.0001 par value per share, of the Company. 

“Company” has the meaning ascribed to it in the introductory paragraph hereto. 

“Company Sale” means: (a) a merger or consolidation in which (i) the Company is a constituent party, or (ii) a
Company Subsidiary is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation, except in the case of either clause (i) or (ii) any such merger or consolidation involving the Company
or a Company Subsidiary in which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock which represent,
immediately following such merger or consolidation, more than 50% by voting power of the capital stock (including, for the purposes of this clause, the capital stock issuable upon conversion of any convertible promissory notes prior to such event)
of (A) the surviving or resulting corporation or (B) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving
or resulting corporation; (b) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or a Company Subsidiary of all or substantially all the assets of the
Company and the Company Subsidiaries taken as a whole (except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned Company Subsidiary); or (c) the sale or transfer, in a single transaction or series of
related transactions, by the stockholders of the Company of more than 50% by voting power of the then-outstanding capital stock of the Company to any person or entity or group of affiliated persons or entities. 

  
 -2- 

 “Company Subsidiary” means any corporation, partnership, trust, limited
liability company or other non-corporate business enterprise in which the Company (or another Company Subsidiary) holds stock or other ownership interests representing (a) more than 50% of the voting power of all outstanding stock or ownership
interests of such entity or (b) the right to receive more than 50% of the net assets of such entity available for distribution to the holders of outstanding stock or ownership interests upon a liquidation or dissolution of such entity. 

“Confidential Information” means any information that is labeled as confidential, proprietary or secret which a Purchaser
obtains from the Company pursuant to financial statements, reports and other materials provided by the Company to such Purchaser pursuant to this Agreement or pursuant to visitation or inspection rights granted hereunder. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor federal statute, and the rules and
regulations of the Commission issued under such Act, as they each may, from time to time, be in effect. 
 “Fidelity” means
Fidelity Management & Research Company. 
 “Fidelity Purchaser” means each of Fidelity Securities Fund: Fidelity
OTC Portfolio, Fidelity Select Portfolios: Biotechnology Portfolio and Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund. 

“Indemnified Party” means a party entitled to indemnification pursuant to Section 2.5. 

“Indemnifying Party” means a party obligated to provide indemnification pursuant to Section 2.5. 

“Initial Public Offering” means the initial underwritten public offering of shares of Common Stock pursuant to an effective
Registration Statement or in a jurisdiction and on a recognized securities exchange outside of the United States provided that such public offering is reasonably equivalent to a public offering in the United States in terms of price, offering
proceeds and regulatory approval. 
 “Initiating Holders” means the Purchasers initiating a request for registration
pursuant to Section 2.1(a) or 2.1(b), as the case may be. 
 “JJDC” means Johnson & Johnson Development
Corporation. 
 “Notice of Acceptance” means a written notice from a Purchaser to the Company containing the information
specified in Section 3.1(b). 
 “Major Investor” means a Purchaser holding shares of Series A Preferred and/or Series A-1
Preferred that are convertible into at least 3,000,000 shares of Common Stock, a Purchaser holding at least 1,000,000 shares of Series B Preferred, a Purchaser holding at least 2,000,000 shares of Series C Preferred, and/or a Purchaser holding at
least 3,000,000 shares of Series D Preferred. 

  
 -3- 

 “MVIL” means Morningside Venture (VI) Investments Limited. 

“Offer” means a written notice of any proposed or intended issuance, sale or exchange of Offered Securities containing the
information specified in Section 3.1(a). 
 “Offered Securities” means (a) any shares of its Common Stock,
(b) any other equity securities of the Company, including, without limitation, shares of preferred stock, (c) any option, warrant or other right to subscribe for, purchase or otherwise acquire any equity securities of the Company, or
(d) any debt securities convertible into capital stock of the Company. 
 “Other Holders” means holders of securities
of the Company (other than Purchasers) who are entitled, by contract with the Company, to have securities included in a Registration Statement. 

“Preferred Stock” means the preferred stock, $0.0001 par value per share, of the Company. 

“Prior Investor Rights Agreement” shall have the meaning ascribed to it in the recitals hereto. 

“Prospectus” means the prospectus included in any Registration Statement, as amended or supplemented by an amendment or
prospectus supplement, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 

“Purchase Agreement” has the meaning ascribed to it in the recitals hereto. 

“Purchaser” has the meaning ascribed to it in the introductory paragraph hereto. 

Qualified IPO” means the closing of the sale of shares of Common Stock to the public in an Initial Public Offering resulting in at
least $45,000,000 of gross proceeds to the Company; provided, that the Common Stock has been listed for trading on a “national securities exchange” registered with the Commission under Section 6 of the Exchange Act. 

“Qualified Purchaser” means a Purchaser that is an “accredited investor” within the meaning of Rule 501(a) under
the Securities Act. 
 “Refused Securities” means those Offered Securities as to which a Notice of Acceptance has not been
given by the Qualified Purchasers pursuant to Section 3.1. 
 “Registrable Shares” means (a) the shares of Common
Stock issued or issuable upon conversion of the Shares, (b) the shares of Common Stock issued or issuable upon exercise of the warrants issued to the Purchasers pursuant to the Series B Purchase Agreement, (c) the shares of Common Stock
issued or issuable upon conversion of the Shares issued or issuable pursuant to the exercise of the Series B Warrants, (d) the shares of Common Stock issued or issuable upon exercise of the warrants issued to the Purchasers pursuant to the
Series C Purchase Agreement, (e) any other shares of Common Stock, and any shares of Common Stock issued or 

  
 -4- 

 
issuable upon the conversion or exercise of any other securities, acquired by the Purchasers and (f) any other shares of Common Stock issued in respect of such shares (because of stock
splits, stock dividends, reclassifications, recapitalizations or similar events); provided, however, that shares of Common Stock which are Registrable Shares shall cease to be Registrable Shares (i) upon any sale pursuant to a
Registration Statement or Rule 144 under the Securities Act, (ii) upon any sale in any manner to a person or entity which is not entitled, pursuant to Section 6, to the rights under this Agreement or (iii) at such time, following
an Initial Public Offering, as they become eligible for sale pursuant to Rule 144(b)(1)(i) under the Securities Act; provided, however, with respect to clause (iii), a period of at least one year, as determined in accordance with
paragraph (d) of Rule 144 under the Securities Act, has elapsed since the later of the date such shares were acquired from the Company or an affiliate of the Company. Wherever reference is made in this Agreement to a request or consent of
holders of a certain percentage of Registrable Shares, the determination of such percentage shall include shares of Common Stock issuable upon conversion of the Shares even if such conversion has not been effected. 

“Registration Expenses” means all expenses incurred by the Company in complying with the provisions of Section 2,
including, without limitation, all registration and filing fees, exchange listing fees, printing expenses, fees and expenses of counsel for the Company and the fees and expenses of one counsel selected by the Selling Stockholders to represent the
Selling Stockholders, state Blue Sky fees and expenses, and the expense of any special audits incident to or required by any such registration, but excluding underwriting discounts, selling commissions and the fees and expenses of Selling
Stockholders’ own counsel (other than the counsel selected to represent all Selling Stockholders). 
 “Registration
Statement” means a registration statement filed by the Company with the Commission for a public offering and sale of securities of the Company (other than a registration statement on Form S-8 or Form S-4, or their successors, or any other form for a similar limited purpose, or any registration statement covering only securities proposed to be issued in exchange for securities or assets of another corporation).

 “Securities Act” means the Securities Act of 1933, as amended, or any successor federal statute, and the rules and
regulations of the Commission issued under such Act, as they each may, from time to time, be in effect. 
 “Selling
Stockholder” means any Purchaser owning Registrable Shares included in a Registration Statement. 
 “Senior
Preferred” means the Series B Preferred, Series C Preferred and Series D Preferred. 
 “Series A Preferred” shall
have the meaning ascribed to it in the recitals hereto. 
 “Series A-1 Preferred” means Series A-1 Preferred Stock, $0.0001
par value per share. 
 “Series B Directors” means the members of the Board of Directors designated by the holders of a
majority of the outstanding shares of Series B Preferred pursuant to the terms of the Amended and Restated Voting Agreement by and between the Company, the Purchasers and the Key Holders named therein of even date herewith. 

  
 -5- 

 “Series B Purchase Agreement” means that certain Series B Preferred Stock
Purchase Agreement, dated April 15, 2011, among the Company and the Purchasers listed on Exhibit A thereto. 

“Series B Preferred” means Series B Preferred Stock, $0.0001 par value per share. 

“Series B Warrants” means warrants for Series B Preferred issued pursuant to the Series B Purchase Agreement. 

“Series C Directors” means the members of the Board of Directors designated by the Purchasers who hold at least 60% of the
outstanding shares of Series C Preferred pursuant to the terms of the Amended and Restated Voting Agreement by and between the Company, the Purchasers and the Key Holders named therein of even date herewith. 

“Series C Preferred” shall have the meaning ascribed to it in the recitals hereto. 

“Series C Purchase Agreement” means that certain Series C Preferred Stock Purchase Agreement, dated May 30, 2014, among
the Company and the Purchasers listed on Exhibit A thereto. 
 “Series D Preferred” shall have the meaning
ascribed to it in the recitals hereto. 
 “Shares” means, collectively, shares of Series A Preferred, Series A-1 Preferred,
Series B Preferred, Series C Preferred and Series D Preferred. 
 “Significant Investor” means a Purchaser holding at least
2,250,000 shares of Series D Preferred. 
 “Undersubscription Amount” means, with respect to a Qualified Purchaser, any
additional portion of the Offered Securities attributable to the Basic Amounts of other Qualified Purchasers as such Qualified Purchaser indicates it will purchase or acquire should the other Qualified Purchasers subscribe for less than their Basic
Amounts. 
 2. Registration Rights. 

2.1 Required Registrations. 

(a) At any time after the earlier of (i) two years after the date of this Agreement or (ii) six months after the
closing of the Initial Public Offering, a Purchaser or Purchasers holding in the aggregate at least a majority of the then outstanding Common Stock issued or issuable upon conversion of the Series C Preferred and Series D Preferred, voting together
as a single class, or a majority of the then outstanding Common Stock issued or issuable upon conversion of the Series B Preferred may request, in writing, that the Company effect the registration on
Form S-1 (or any successor form) of Registrable Shares owned by such Purchaser or Purchasers having an aggregate value of at least $5,000,000 (based on the market price or fair value on the date of such
request). 

  
 -6- 

 (b) At any time after the Company becomes eligible to file a Registration
Statement on Form S-3 (or any successor form relating to secondary offerings), a Purchaser or Purchasers holding Registrable Shares may request, in writing, that the Company effect the registration on Form S-3 (or such successor form), of Registrable Shares having an aggregate value of at least $1,500,000 (based on the public market price on the date of such request). 

(c) Upon receipt of any request for registration pursuant to this Section 2, the Company shall promptly give written
notice of such proposed registration to all other Purchasers. Such Purchasers shall have the right, by giving written notice to the Company within 30 days after the Company provides its notice, to elect to have included in such registration such of
their Registrable Shares as such Purchasers may request in such notice of election, subject in the case of an underwritten offering to the terms of Section 2.1(d); provided, that holders of the Senior Preferred will have first priority
over other Purchasers to have their shares included in any such registrations. Thereupon, the Company shall, as expeditiously as possible, use its best efforts to effect the registration on an appropriate registration form of all Registrable Shares
which the Company has been requested to so register; provided, however, that in the case of a registration requested under Section 2.1(b), the Company will only be obligated to effect such registration on Form S-3 (or any
successor form). 
 (d) If the Initiating Holders intend to distribute the Registrable Shares covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1(a) or (b), as the case may be, and the Company shall include such information in its written notice referred to in
Section 2.1(c). In such event, (i) the right of any other Purchaser to include its Registrable Shares in such registration pursuant to Section 2.1(a) or (b), as the case may be, shall be conditioned upon such other Purchaser’s
participation in such underwriting on the terms set forth herein, and (ii) all Purchasers including Registrable Shares in such registration shall enter into an underwriting agreement upon customary terms with the underwriter or underwriters
managing the offering; provided that such underwriting agreement shall not provide for indemnification or contribution obligations on the part of the Purchasers materially greater than the obligations of the Purchasers pursuant to
Section 2.5. The Initiating Holders shall have the right to select the managing underwriter(s) for any underwritten offering requested pursuant to Section 2.1(a) or (b), subject to the approval of the Company, which approval will not be
unreasonably withheld, conditioned or delayed. If any Purchaser who has requested inclusion of its Registrable Shares in such registration as provided above disapproves of the terms of the underwriting, such Purchaser may elect, by written notice to
the Company, to withdraw its Registrable Shares from such Registration Statement and underwriting. If the managing underwriter advises the Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the
number of Registrable Shares to be included in the Registration Statement and underwriting shall be allocated among 

  
 -7- 

 
all Purchasers requesting registration in proportion, as nearly as practicable, to the respective number of Registrable Shares held by them on the date of the request for registration made by the
Initiating Holders pursuant to Section 2.1(a) or (b), as the case may be. If any Purchaser would thus be entitled to include more Registrable Shares than such Purchaser requested to be registered, the excess shall be allocated among other
requesting Purchasers pro rata in the manner described in the preceding sentence. 
 (e) The Company shall not be required
to effect more than two registrations pursuant to Section 2.1(a). In addition, the Company shall not be required to effect any registration within six months after the effective date of the Registration Statement relating to the Initial Public
Offering. For purposes of this Section 2.1(e), a Registration Statement shall not be counted until such time as such Registration Statement has been declared effective by the Commission (unless the Initiating Holders withdraw their request for
such registration (other than as a result of information concerning the business or financial condition of the Company which is made known to the Purchasers after the date on which such registration was requested) and elect not to pay the
Registration Expenses therefor pursuant to Section 2.4). For purposes of this Section 2.1(e), a Registration Statement shall not be counted if, as a result of an exercise of the underwriter’s cut-back provisions, less than 50% of the
total number of Registrable Shares that Purchasers have requested to be included in such Registration Statement are so included. 

(f) If at the time of any request to register Registrable Shares by Initiating Holders pursuant to this Section 2.1, the
Company is engaged or has plans to engage in a registered public offering or is engaged in any other activity which, in the good faith determination of the Company’s Board of Directors, would be adversely affected by the requested registration,
then the Company may at its option direct that such request be delayed for a period not in excess of 90 days from the date of such request, such right to delay a request to be exercised by the Company not more than once in any 12-month period. 

2.2 Incidental Registration. 

(a) Whenever the Company proposes to file a Registration Statement (other than a Registration Statement filed pursuant to
Section 2.1) at any time and from time to time, it will, prior to such filing, give written notice to all Purchasers of its intention to do so. Upon the written request of a Purchaser or Purchasers given within 20 days after the Company
provides such notice (which request shall state the intended method of disposition of such Registrable Shares), the Company shall use its best efforts to cause all Registrable Shares which the Company has been requested by such Purchaser or
Purchasers to register to be registered under the Securities Act to the extent necessary to permit their sale or other disposition in accordance with the intended methods of distribution specified in the request of such Purchaser or Purchasers;
provided that the Company shall have the right to postpone or withdraw any registration effected pursuant to this Section 2.2 without obligation to any Purchaser. 

  
 -8- 

 (b) If the registration for which the Company gives notice pursuant to
Section 2.2(a) is a registered public offering involving an underwriting, the Company shall so advise the Purchasers as a part of the written notice given pursuant to Section 2.2(a). In such event, (i) the right of any Purchaser to
include its Registrable Shares in such registration pursuant to this Section 2.2 shall be conditioned upon such Purchaser’s participation in such underwriting on the terms set forth herein and (ii) all Purchasers including Registrable
Shares in such registration shall enter into an underwriting agreement upon customary terms with the underwriter or underwriters selected for the underwriting by the Company; provided that such underwriting agreement shall not provide for
indemnification or contribution obligations on the part of Purchasers materially greater than the obligations of the Purchasers pursuant to Section 2.5. If any Purchaser who has requested inclusion of its Registrable Shares in such registration
as provided above disapproves of the terms of the underwriting, such person may elect, by written notice to the Company, to withdraw its shares from such Registration Statement and underwriting. If the managing underwriter advises the Company in
writing that marketing factors require a limitation on the number of shares to be underwritten, the shares held by holders of securities of the Company other than Purchasers and Other Holders shall be excluded from such Registration Statement and
underwriting to the extent deemed advisable by the managing underwriter, and, if a further reduction of the number of shares is required, the number of shares that may be included in such Registration Statement and underwriting shall be allocated
first to all Purchasers holding Senior Preferred requesting registration in proportion, as nearly as practicable, to the respective number of shares of Common Stock (on an as-converted basis) held by them on the date the Company gives the notice
specified in Section 2.2(a). If any Purchasers holding Senior Preferred would be entitled to include more shares than such holder requested to be registered, the excess shall be allocated first among the other Purchasers holding Senior
Preferred pro rata in the manner described in the preceding sentence and, if there remains any shares that may be included, next among all other Purchasers and Other Holders requesting registration in proportion, as nearly as practicable, to the
respective number of shares of Common Stock (on an as-converted basis) held by them on the date the Company gives the notice specified in Section 2.2(a); provided that, unless such registration is in connection with the Company’s
Initial Public Offering, the number of Registrable Shares permitted to be included therein shall in any event be at least 20% of the securities included therein. If any Purchaser or Other Holder would be entitled to include more shares than such
holder requested to be registered, the excess shall be allocated among other requesting Purchasers and Other Holders pro rata in the manner described in the preceding sentence. 

2.3 Registration Procedures. 

(a) If and whenever the Company is required by the provisions of this Agreement to use its best efforts to effect the
registration of any Registrable Shares under the Securities Act, the Company shall: 
 (i) file with the Commission a Registration
Statement with respect to such Registrable Shares and use its best efforts to cause that Registration Statement to become effective as soon as possible; 

  
 -9- 

 (ii) as expeditiously as possible prepare and file with the Commission any amendments and
supplements to the Registration Statement and the prospectus included in the Registration Statement as may be necessary to comply with the provisions of the Securities Act (including the anti-fraud provisions thereof) and to keep the Registration
Statement effective for 12 months from the effective date or such lesser period until all such Registrable Shares are sold; 
 (iii) as
expeditiously as possible furnish to each Selling Stockholder such reasonable numbers of copies of the Prospectus, including any preliminary Prospectus, in conformity with the requirements of the Securities Act, and such other documents as such
Selling Stockholder may reasonably request in order to facilitate the public sale or other disposition of the Registrable Shares owned by such Selling Stockholder; 

(iv) as expeditiously as possible use its best efforts to register or qualify the Registrable Shares covered by the Registration Statement
under the securities or Blue Sky laws of such states as the Selling Stockholders shall reasonably request, and do any and all other acts and things that may be necessary or desirable to enable the Selling Stockholders to consummate the public sale
or other disposition in such states of the Registrable Shares owned by the Selling Stockholders; provided, however, that the Company shall not be required in connection with this paragraph (iv) to qualify as a foreign corporation or to execute
a general consent to service of process in any jurisdiction or to amend its Charter or By-laws in a manner that the Board of Directors of the Company determines is inadvisable; 

(v) as expeditiously as possible, cause all such Registrable Shares to be listed on each securities exchange or automated quotation system on
which similar securities issued by the Company are then listed; 
 (vi) promptly provide a transfer agent and registrar for all such
Registrable Shares not later than the effective date of such Registration Statement; 
 (vii) promptly make available for inspection by the
Selling Stockholders, any managing underwriter participating in any disposition pursuant to such Registration Statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the Selling Stockholders, all
financial and other records, pertinent corporate documents and properties of the Company and cause the Company’s officers, directors, employees and independent accountants to supply all information reasonably requested by any such seller,
underwriter, attorney, accountant or agent in connection with such Registration Statement; 
 (viii) notify each Selling Stockholder,
promptly after it shall receive notice thereof, of the time when such Registration Statement has become effective or a supplement to any Prospectus forming a part of such Registration Statement has been filed; and 

(ix) as expeditiously as possible following the effectiveness of such Registration Statement, notify each seller of such Registrable Shares
of any request by the Commission for the amending or supplementing of such Registration Statement or Prospectus. 

  
 -10- 

 (b) If the Company has delivered a Prospectus to the Selling Stockholders and
after having done so the Prospectus is amended to comply with the requirements of the Securities Act, the Company shall promptly notify the Selling Stockholders and, if requested, the Selling Stockholders shall immediately cease making offers of
Registrable Shares and return all Prospectuses to the Company. The Company shall promptly provide the Selling Stockholders with revised Prospectuses and, following receipt of the revised Prospectuses, the Selling Stockholders shall be free to resume
making offers of the Registrable Shares. 
 (c) In the event that, in the judgment of the Company, it is advisable to
suspend use of a Prospectus included in a Registration Statement due to pending material developments or other events that have not yet been publicly disclosed and as to which the Company believes public disclosure would be detrimental to the
Company, the Company shall notify all Selling Stockholders to such effect, and, upon receipt of such notice, each such Selling Stockholder shall immediately discontinue any sales of Registrable Shares pursuant to such Registration Statement until
such Selling Stockholder has received copies of a supplemented or amended Prospectus or until such Selling Stockholder is advised in writing by the Company that the then current Prospectus may be used and has received copies of any additional or
supplemental filings that are incorporated or deemed incorporated by reference in such Prospectus. Notwithstanding anything to the contrary herein, the Company shall not exercise its rights under this Section 2.3(c) to suspend sales of
Registrable Shares for a period in excess of 30 days consecutively or 60 days in any 365-day period. 
 2.4 Allocation of
Expenses. The Company will pay all Registration Expenses for all registrations under this Agreement; provided, however, that if a registration under Section 2.1 is withdrawn at the request of the Initiating Holders (other than
as a result of information concerning the business or financial condition of the Company which is made known to the Selling Stockholders after the date on which such registration was requested) and if the Initiating Holders elect not to have such
registration counted as a registration requested under Section 2.1, the Selling Stockholders shall pay the Registration Expenses of such registration pro rata in accordance with the number of their Registrable Shares included in such
registration. 
 2.5 Indemnification and Contribution. 

(a) In the event of any registration of any of the Registrable Shares under the Securities Act pursuant to this Agreement, the
Company will indemnify and hold harmless each Selling Stockholder, each underwriter of such Registrable Shares, and each other person, if any, who controls such Selling Stockholder or underwriter within the meaning of the Securities Act or the
Exchange Act against any losses, claims, damages or liabilities, joint or several, to which such Selling Stockholder, underwriter or controlling person may become subject under the Securities Act, the Exchange Act, state securities or Blue Sky laws
or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in any Registration
Statement under which such Registrable Shares were registered under the Securities Act, 

  
 -11- 

 
any preliminary prospectus or final prospectus contained in the Registration Statement, or any amendment or supplement to such Registration Statement, (ii) the omission or alleged omission
to state a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or
any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the Registration Statement or the offering contemplated thereby; and the Company will reimburse such Selling Stockholder,
underwriter and each such controlling person for any legal or any other expenses reasonably incurred by such Selling Stockholder, underwriter or controlling person in connection with investigating or defending any such loss, claim, damage, liability
or action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any untrue statement or omission made in such Registration
Statement, preliminary prospectus or prospectus, or any such amendment or supplement, in reliance upon and in conformity with information furnished to the Company, in writing, by or on behalf of such Selling Stockholder, underwriter or controlling
person specifically for use in the preparation thereof. 
 (b) In the event of any registration of any of the Registrable
Shares under the Securities Act pursuant to this Agreement, each Selling Stockholder, severally and not jointly, will indemnify and hold harmless the Company, each of its directors and officers and each underwriter (if any) and each person, if any,
who controls the Company or any such underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages or liabilities, joint or several, to which the Company, such directors and officers, underwriter or
controlling person may become subject under the Securities Act, Exchange Act, state securities or Blue Sky laws or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon
(i) any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement under which such Registrable Shares were registered under the Securities Act, any preliminary prospectus or final prospectus
contained in the Registration Statement, or any amendment or supplement to the Registration Statement, or (ii) any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein
not misleading, if and to the extent (and only to the extent) that the statement or omission was made in reliance upon and in conformity with information relating to such Selling Stockholder furnished in writing to the Company by such Selling
Stockholder specifically for use in connection with the preparation of such Registration Statement, prospectus, amendment or supplement; provided, however, that the obligations of a Selling Stockholder hereunder shall be limited to an
amount equal to the net proceeds to such Selling Stockholder of Registrable Shares sold in connection with such registration. 

(c) Each Indemnified Party shall give notice to the Indemnifying Party promptly after such Indemnified Party has actual
knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom; provided, that counsel for the Indemnifying Party, who shall
conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not be 

  
 -12- 

 
unreasonably withheld, conditioned or delayed); and, provided, further, that the failure of any Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Section 2.5 except to the extent that the Indemnifying Party is adversely affected by such failure. The Indemnified Party may participate in such defense at such party’s expense;
provided, however, that the Indemnifying Party shall pay such expense if the Indemnified Party reasonably concludes that representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate
due to actual or potential differing interests between the Indemnified Party and any other party represented by such counsel in such proceeding; provided further that in no event shall the Indemnifying Party be required to pay the expenses of
more than one law firm per jurisdiction as counsel for the Indemnified Party. The Indemnifying Party also shall be responsible for the expenses of such defense if the Indemnifying Party does not elect to assume such defense. No Indemnifying Party,
in the defense of any such claim or litigation shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such Indemnified Party of a release from all liability in respect of such claim or litigation, and no Indemnified Party shall consent to entry of any judgment or settle such claim or litigation without the prior written consent of
the Indemnifying Party, which consent shall not be unreasonably withheld, conditioned or delayed. 
 (d) In order to provide
for just and equitable contribution in circumstances in which the indemnification provided for in this Section 2.5 is due in accordance with its terms but for any reason is held to be unavailable to an Indemnified Party in respect to any
losses, claims, damages and liabilities referred to herein, then the Indemnifying Party shall, in lieu of indemnifying such Indemnified Party, contribute to the amount paid or payable by such Indemnified Party as a result of such losses, claims,
damages or liabilities to which such party may be subject in such proportion as is appropriate to reflect the relative fault of the Company on the one hand and the Selling Stockholders on the other in connection with the statements or omissions
which resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative fault of the Company and the Selling Stockholders shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of material fact related to information supplied by the Company or the Selling Stockholders and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission. The Company and the Selling Stockholders agree that it would not be just and equitable if contribution pursuant to this Section 2.5(d) were determined by pro rata allocation or by any other method of allocation which does
not take account of the equitable considerations referred to above. Notwithstanding the provisions of this Section 2.5(d), (i) in no case shall any one Selling Stockholder be liable or responsible for any amount in excess of the net
proceeds received by such Selling Stockholder from the offering of Registrable Shares and (ii) the Company shall be liable and responsible for any amount in excess of such proceeds; provided, however, that no person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. Any party entitled to contribution will,
promptly after receipt of notice of commencement of any action, suit or 

  
 -13- 

 
proceeding against such party in respect of which a claim for contribution may be made against another party or parties under this Section 2.5(d), notify such party or parties from whom
contribution may be sought, but the omission so to notify such party or parties from whom contribution may be sought shall not relieve such party from any other obligation it or they may have thereunder or otherwise under this Section 2.5(d).
No party shall be liable for contribution with respect to any action, suit, proceeding or claim settled without its prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. 

(e) The rights and obligations of the Company and the Selling Stockholders under this Section 2.5 shall survive the
termination of this Agreement. 
 2.6 Other Matters with Respect to Underwritten Offerings. In the event that
Registrable Shares are sold pursuant to a Registration Statement in an underwritten offering pursuant to Section 2.1, the Company agrees to (a) enter into an underwriting agreement containing customary representations and warranties with
respect to the business and operations of the Company and customary covenants and agreements to be performed by the Company, including without limitation customary provisions with respect to indemnification by the Company of the underwriters of such
offering; (b) use its best efforts to cause its legal counsel to render customary opinions to the underwriters and the Selling Stockholders with respect to the Registration Statement; and (c) use its best efforts to cause its independent
public accounting firm to issue customary “cold comfort letters” to the underwriters and the Selling Stockholders with respect to the Registration Statement. 

2.7 Information by Holder. Each holder of Registrable Shares included in any registration shall furnish to the Company
such information regarding such holder and the distribution proposed by such holder as the Company may reasonably request in writing and as shall be required in connection with any registration, qualification or compliance referred to in this
Agreement. 
 2.8 “Lock-Up” Agreement; Confidentiality of Notices. Each Purchaser agrees, if requested by
the Company and the managing underwriter of the Initial Public Offering (but not for any subsequent offerings), (i) not to (a) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Registrable Shares or other securities of the Company (excluding securities acquired in the
Initial Public Offering or in the public market after such offering) or (b) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any Registrable Shares or other securities
of the Company (excluding securities acquired in the Initial Public Offering or in the public market after such offering), whether any transaction described in clause (a) or (b) is to be settled by delivery of securities, in cash or
otherwise, during the period beginning on the date of the filing of such registration statement with the Securities and Exchange Commission and ending on the date specified by the Company and the managing underwriter (such period not to exceed 180
days in the case of the Initial Public Offering or such other period not 

  
 -14- 

 
to exceed 18 days after the expiration of the 180-day period, as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other
distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), and
(ii) to execute any agreement reflecting clause (i) above as may be requested by the Company or the managing underwriters at the time of such offering; provided, that all stockholders of the Company then holding at least 1% of the
outstanding Common Stock (on an as-converted basis) and all officers and directors of the Company enter into similar agreements; provided further, that the foregoing restrictions shall not apply to securities of the Company purchased
by a Purchaser on the open market following the Initial Public Offering or in the Initial Public Offering, if and only if (i) such sales are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance with
Section 16 of the Exchange Act during such period, and (ii) such Purchaser does not otherwise voluntarily effect any public filing or report regarding such sales (it being understood that reporting daily holdings on a website or other
publicly available resource by a Purchaser that is a registered investment company shall not be considered a public filing or report for purposes of this subsection (ii)). 

The Company may impose stop-transfer instructions with respect to the Registrable Shares or other securities subject to the foregoing
restriction until the end of such “lock-up” period. 
 As a condition to the obligation of the Purchasers under this
Section 2.8, any “lock-up” obligation of the Purchasers under this Section 2.8, and any agreement entered into by the Purchasers as a result of their obligations under this Section 2.8, shall (i) allow for periodic
early releases of portions of the securities subject to such “lock-up” obligations, which may be conditioned upon the trading price of the Company’s Common Stock and (ii) provide that all Purchasers will participate on a pro-rata
basis in any early release of any stockholder. 
 Any Purchaser receiving any written notice from the Company regarding the Company’s
plans to file a Registration Statement shall treat such notice confidentially and shall not disclose such information to any person other than as necessary to exercise its rights under this Agreement. 

2.9 Limitations on Subsequent Registration Rights. The Company shall not, without the prior written consent of
Purchasers holding in the aggregate at least a majority of the then outstanding Common Stock issued or issuable upon conversion of the Series C Preferred and Series D Preferred, voting together as a single class, and a majority of the then
outstanding Common Stock issued or issuable upon conversion of the Series B Preferred, enter into any agreement (other than this Agreement) with any holder or prospective holder of any securities of the Company which grants such holder or
prospective holder rights to include securities of the Company in any Registration Statement, unless (a) such rights to include securities in a registration initiated by the Company or by Purchasers are not more favorable than the rights
granted to Other Holders under Section 2.2, and (b) no rights are granted to initiate a registration, other than registration pursuant to a registration statement on Form S-3 (or its successor) in

  
 -15- 

 
which Purchasers are entitled to include Registrable Shares on a pro rata basis with such holders based on the number of shares of Common Stock (on an as-converted basis) owned by Purchasers and
such holders. 
 2.10 Rule 144 Requirements. After the earliest of (i) the closing of the sale of securities of
the Company pursuant to a Registration Statement, (ii) the registration by the Company of a class of securities under Section 12 of the Exchange Act, or (iii) the issuance by the Company of an offering circular pursuant to Regulation
A under the Securities Act, the Company agrees to: 
 (a) make and keep current public information about the Company
available, as those terms are understood and defined in Rule 144; 
 (b) use its best efforts to file with the Commission in
a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 

(c) furnish to any holder of Registrable Shares upon request (i) a written statement by the Company as to its compliance
with the reporting requirements of Rule 144 and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), (ii) a copy of the most recent annual or quarterly report of the Company, and
(iii) such other reports and documents of the Company as such holder may reasonably request to avail itself of any similar rule or regulation of the Commission allowing it to sell any such securities without registration. 

2.11 Registration in Other Jurisdictions. In the event that the Company effects an Initial Public Offering in a
jurisdiction other than the United States, the Purchasers shall be entitled to registration rights in such jurisdiction as substantially equivalent as possible to those set forth in this Section 2. In such case, all references in this
Section 2 to any regulatory authority, forms and rules and regulations applicable to a registration in the United States shall be deemed to refer instead to the equivalent such regulatory authority, forms and rules and regulations of the
jurisdiction in which the Company effected the Initial Public Offering and the Company agrees to comply in all material respects with the laws of the jurisdiction in which the Company effects such an Initial Public Offering as if such Initial Public
Offering were effected in the United States. 
 2.12 Termination. All of the Company’s obligations to register
Registrable Shares under Sections 2.1 and 2.2 shall terminate upon the earliest of (a) five years after the closing of a Qualified IPO, (b) the date on which no Purchaser holds any Registrable Shares or (c) a Company Sale. 

  
 -16- 

 3. Right of First Refusal. 

3.1 Rights of Purchasers to Acquire Offered Securities. 

(a) The Company shall not issue, sell or exchange, agree to issue, sell or exchange, or reserve or set aside for issuance,
sale or exchange, any Offered Securities, unless in each such case the Company shall have first complied with this Section 3.1. The Company shall deliver to each Purchaser holding Senior Preferred an Offer, which shall (i) identify and
describe the Offered Securities, (ii) describe the price and other terms upon which they are to be issued, sold or exchanged, and the number or amount of the Offered Securities to be issued, sold or exchanged, (iii) identify the persons or
entities (if known) to which or with which the Offered Securities are to be offered, issued, sold or exchanged, and (iv) offer to issue and sell to or exchange with such Purchaser that is a Qualified Purchaser (A) such Qualified
Purchaser’s Basic Amount and (B) such Qualified Purchaser’s Undersubscription Amount. 
 (b) To accept an
Offer, in whole or in part, a Qualified Purchaser must deliver to the Company, on or prior to the date 30 days after the date of delivery of the Offer, a Notice of Acceptance providing a representation letter certifying that such Qualified Purchaser
is an accredited investor within the meaning of Rule 501 under the Securities Act and indicating the portion of the Qualified Purchaser’s Basic Amount that such Qualified Purchaser elects to purchase and, if such Qualified Purchaser shall elect
to purchase all of its Basic Amount, the Undersubscription Amount (if any) that such Qualified Purchaser elects to purchase. If the Basic Amounts subscribed for by all Qualified Purchasers are less than the total of all of the Basic Amounts
available for purchase, then each Qualified Purchaser who has set forth an Undersubscription Amount in its Notice of Acceptance shall be entitled to purchase, in addition to the Basic Amounts subscribed for, the Undersubscription Amount it has
subscribed for; provided, however, that if the Undersubscription Amounts subscribed for exceed the Available Undersubscription Amount, each Qualified Purchaser who has subscribed for any Undersubscription Amount shall be entitled to
purchase only that portion of the Available Undersubscription Amount as the Undersubscription Amount subscribed for by such Qualified Purchaser bears to the total Undersubscription Amounts subscribed for by all Purchasers, subject to rounding by the
Board of Directors to the extent it deems reasonably necessary. 
 (c) The Company shall have 90 days from the expiration of
the period set forth in Section 3.1(b) to issue, sell or exchange all or any part of the Refused Securities, but only to the offerees or purchasers described in the Offer (if so described therein) and only upon terms and conditions (including,
without limitation, unit prices and interest rates) which are not more favorable, in the aggregate, to the acquiring person or persons or less favorable to the Company than those set forth in the Offer. 

(d) In the event the Company shall propose to sell less than all the Refused Securities, then each Qualified Purchaser may, at
its sole option and in its sole discretion, reduce the number or amount of the Offered Securities specified in its Notice of Acceptance to an amount that shall be not less than the number or amount of

  
 -17- 

 
the Offered Securities that the Qualified Purchaser elected to purchase pursuant to Section 3.1(b) multiplied by a fraction, (i) the numerator of which shall be the number or amount of
Offered Securities the Company actually proposes to issue, sell or exchange (including Offered Securities to be issued or sold to Qualified Purchasers pursuant to Section 3.1(b) prior to such reduction) and (ii) the denominator of which
shall be the original amount of the Offered Securities. In the event that any Qualified Purchaser so elects to reduce the number or amount of Offered Securities specified in its Notice of Acceptance, the Company may not issue, sell or exchange more
than the reduced number or amount of the Offered Securities unless and until such securities have again been offered to the Qualified Purchasers in accordance with Section 3.1(a). 

(e) Upon (i) the closing of the issuance, sale or exchange of all or less than all of the Refused Securities or
(ii) such other date agreed to by the Company and Qualified Purchasers who have subscribed for a majority of the Offered Securities subscribed for by the Qualified Purchasers, such Qualified Purchaser or Purchasers shall acquire from the
Company and the Company shall issue to such Qualified Purchaser or Purchasers, the number or amount of Offered Securities specified in the Notices of Acceptance, as reduced pursuant to Section 3.1(d) if any of the Qualified Purchasers has so
elected, upon the terms and conditions specified in the Offer. 
 (f) The purchase by the Qualified Purchasers of any
Offered Securities is subject in all cases to the preparation, execution and delivery by the Company and the Qualified Purchasers of a purchase agreement relating to such Offered Securities reasonably satisfactory in form and substance to the
Qualified Purchasers and their respective counsel. 
 (g) Any Offered Securities not acquired by the Qualified Purchasers or
other persons in accordance with Section 3.1(c) may not be issued, sold or exchanged until they are again offered to the Qualified Purchasers under the procedures specified in this Agreement. 

(h) The rights of the Qualified Purchasers under this Section 3.1 shall not apply to: 

(i) the issuance of any shares of Common Stock as a stock dividend to holders of Common Stock or upon any subdivision or combination of
shares of Common Stock; 
 (ii) the issuance of any shares of Common Stock upon conversion of shares of convertible preferred stock; 

(iii) the issuance of shares of Common Stock or convertible securities issued or issuable upon conversion or exchange of any convertible
securities or exercise of any options outstanding as of the date of this Agreement, in each case provided such issuance is pursuant to the terms of such option or convertible security; 

(iv) the issuance of up to 12,674,545 shares of Common Stock, or options with respect thereto, (subject in either case to appropriate
adjustment for stock splits, 

  
 -18- 

 
stock dividends, recapitalizations and similar events occurring after the date of this Agreement), issued or issuable to employees, directors or officers of, or consultants to, the Company or any
Company Subsidiary pursuant to any plan, agreement or arrangement approved by the Board of Directors of the Company, including by a majority of the members of the Board of Directors who are not employees of the Company or a Company Subsidiary (it
being understood that that any shares of Common Stock (i) not issued pursuant to rights, agreements, option or warrants (“Unexercised Options”) as a result of the termination of such Unexercised Options or (ii) reacquired
by the Company from employees, directors or consultants at no more than cost pursuant to agreements that permit the Company to repurchase such shares upon termination of services to the Company shall not be counted toward such maximum number unless
and until such shares are regranted as shares of Common Stock and/or options, warrants or other Common Stock purchase rights); 
 (v) the
issuance of shares of Common Stock, options or convertible securities issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing
transaction approved by the Board of Directors of the Company that do not exceed an aggregate of 2% of the shares of Common Stock outstanding immediately prior to such issuance (treating for this purpose as outstanding all shares of Common Stock
issuable upon exercise of options outstanding immediately prior to such issue (whether or not vested) or upon conversion or exchange of convertible securities (including shares of Preferred Stock) outstanding (assuming exercise of any outstanding
options therefor) immediately prior to such issue); 
 (vi) the issuance of shares of Common Stock, options or convertible securities
issued in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors of the Company that do not exceed an aggregate of
2% of the shares of Common Stock outstanding immediately prior to such issuance (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of options outstanding immediately prior to such issue (whether or not
vested) or upon conversion or exchange of convertible securities (including shares of Preferred Stock) outstanding (assuming exercise of any outstanding options therefor) immediately prior to such issue); or 

(vii) the issuance of shares of Common Stock by the Company in a firm-commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act. 
 3.2 Waiver. In the event that the Purchasers waive the rights set forth in
Section 3.1 above, and a Purchaser or any other then-current shareholder of the Company acquires Offered Securities, then the Company shall provide written notice of such sale to each Major Investor that did not consent to such waiver (the
“Non-Consenting Major Investors”) within 30 days after the issuance of the Offered Securities. Each Non-Consenting Major Investor shall have 20 days from the date notice is given to elect to purchase such Non-Consenting Major
Investor’s Basic Amount of the Offered Securities. The closing of such sale shall occur within 60 days of the date notice is given to the Non-Consenting Major Investors. 

  
 -19- 

 3.3 Termination. This Section 3 shall terminate upon the earlier of
the closing of a Company Sale or the closing of a Qualified IPO. 
 4. Covenants. 

4.1 Negative Covenants. So long as the holders of the Series B Preferred are entitled to elect at least one Series B
Director and/or holders of the Series C Preferred are entitled to elect at least one Series C Director, the Company shall not, without approval of the Board of Directors) (such approval to include the prior approval of at least one Series B Director
and at least one Series C Director for the purposes of Section 4.1(i)): 
 (a) adopt or implement the annual plan
prepared by management with respect to the Company’s budget or business plan; 
 (b) implement any material deviation,
individually or in the aggregate, from the amounts set forth in the budgets in excess of thresholds approved by the Board of Directors and part of the budget setting process; 

(c) incur any aggregate indebtedness in excess of $50,000, that is not already included in a budget approved by the Board of
Directors; 
 (d) pledge, lease, grant a security interest in, or encumber any of the Company’s assets in connection
with the incurrence of indebtedness; 
 (e) hire an employee at the level of Vice President or above; 

(f) terminate the employment of or change in any material manner the compensation of any executive officer, including
approving any option grants or stock awards to executive officers; 
 (g) enter into any contract or transaction (or amend
any existing contracts or transactions) with any shareholder, director, officer, or other insider or any of their family members or affiliates other than on an arms-length basis and upon full disclosure to stockholders; 

(h) repurchase Common Stock or Shares; or 

(i) materially change the principal business of the Company, enter new lines of business, or exit the current lines of
business. 
 4.2 Affirmative Covenants. So long as any Shares are outstanding, the Company covenants and agrees that
it will perform and observe the following covenants and provisions and will cause each Company Subsidiary to perform and observe such of the following covenants and provisions as are applicable to such Company Subsidiary: 

  
 -20- 

 (a) Payment of Taxes and Trade Debt. Pay and discharge all taxes,
assessments and governmental charges or levies imposed upon it or upon its income or profits or business, or upon any properties belonging to it, prior to the date on which penalties attach thereto, and all lawful claims, which, if unpaid, might
become a lien or charge upon any properties of the Company or a Company Subsidiary, other than those which are being contested in good faith if the Company shall have set aside on its books and shall have provided, in accordance with generally
accepted accounting principles, adequate reserves with respect thereto; and pay in conformity with customary trade terms, all lease obligations, all trade debt, and all other indebtedness incident to its operations, except such as are being
contested in good faith if the Company shall have set aside on its books and shall have provided, in accordance with generally accepted accounting principles, appropriate reserves with respect thereto. 

(b) Maintenance of Insurance. Maintain with responsible and reputable insurance companies or associations, insurance in
such amounts and covering such risks as the Company reasonably deems advisable. The Company shall use commercially reasonable efforts to obtain or maintain directors and officers liability insurance in the amount of $2,000,000 (or such other amount
acceptable to the Board of Directors), provided that such insurance can be obtained or maintained at a reasonable cost to the Company. 

(c) Preservation of Corporate Existence. Preserve and maintain its corporate existence, rights, franchises and
privileges in the jurisdiction of its incorporation, and qualify and remain qualified as a foreign corporation in each jurisdiction in which such qualification is required, unless the failure to so qualify does not and will not have a material and
adverse effect on the business, operations or financial condition of the Company; and preserve and maintain all material licenses and other rights to use patents, processes, licenses, trademarks, trade names, inventions, intellectual property rights
or copyrights owned or possessed by it as are reasonably necessary or advisable for it to conduct its business. 
 (d)
Compliance with Laws. Comply with all applicable laws, rules, regulations and orders of any governmental authority, noncompliance with which could materially adversely affect its business or condition, financial or otherwise, except
non-compliance being contested in good faith through appropriate proceedings so long as the Company shall have set up and funded sufficient reserves, if any, required under generally accepted accounting principles with respect to such items. 

(e) Keeping of Records and Books of Account. Keep adequate records and books of account, in which complete entries will
be made in accordance with generally accepted accounting principles consistently applied, reflecting all financial transactions of the Company, and in which, for each fiscal year, all proper reserves for depreciation, depletion, obsolescence,
amortization, taxes, bad debts and other purposes in connection within its business shall be made. 
 (f) Maintenance of
Properties, etc. Maintain and preserve all of its properties that the Company reasonably deems necessary or useful in the proper conduct of its business in good repair, working order and condition, ordinary wear and tear excepted, and from time
to time make all necessary and proper repairs, renewals, 

  
 -21- 

 
replacements, additions and improvements thereto; and comply with the provisions of all material leases to which it is a party or under which it occupies property so as to prevent any material
loss or forfeiture thereof or thereunder. 
 4.3 Inspection and Observation. The Company shall permit each Major
Investor, or any authorized representative thereof, to visit and inspect the properties of the Company, including its corporate and financial records, and to discuss its business and finances with officers of the Company, during normal business
hours following reasonable notice and as often as may be reasonably requested. 
 4.4 Financial Statements and Other
Information. 
 (a) The Company shall deliver to (i) each Major Investor and (ii) each Fidelity Purchaser:

 (i) within 120 days after the end of each fiscal year of the Company, an audited balance sheet of the Company as at the end of such
year and audited statements of operations, and of cash flows of the Company for such year, certified by certified public accountants of established national reputation selected by the Company (which public accountants shall be reasonably acceptable
to the Board of Directors), and prepared in accordance with generally accepted accounting principles of the United States consistently applied; and 

(ii) within 45 days after the end of each fiscal quarter of the Company (other than the fourth quarter), an unaudited balance sheet of the
Company as at the end of such quarter, and unaudited statements of operations, and of cash flows of the Company for such fiscal quarter and for the current fiscal year to the end of such fiscal quarter, setting forth in comparative form such results
against (a) the prior year comparable period and (b) the Company’s projected financial statements for the corresponding periods for the current fiscal year. 

(iii) within 60 days after the end of each month, an executive summary of the Company’s activities; 

(iv) within 60 days after the end of each fiscal year, a notice advising the stockholders as to its status as a “passive foreign
investment company” or a “controlled foreign corporation” for United States federal income tax purposes and provide each such stockholder with necessary information to complete its tax filings and elections with respect thereto; 

(v) as soon as available, but in any event prior to the commencement of each new fiscal year, a business plan and operating budget for such
fiscal year, in reasonable detail and broken down on a quarterly basis; 
 (vi) such other notices, information and data with respect to
the Company as the Company delivers to the holders of its capital stock at the same time it delivers such items to such holders; 

  
 -22- 

 (vii) to the extent requested in writing by a Major Investor, such other notices, information
and data with respect to the Company as the Company delivers to the Board; provided, however, that the Company shall not be obligated under this subsection to provide information (a) that the Company reasonably determines in good
faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company); or (b) the disclosure of which would adversely affect the attorney-client
privilege between the Company and its counsel. 
 (viii) with respect to any proposed Company Sale, Initial Public Offering, or other
significant event that requires stockholder approval, timely notice of such proposed transaction and such stockholders shall be afforded at least five business days to review the final agreements relating thereto; and 

(ix) with reasonable promptness, such other information and data as such Purchaser may from time to time reasonably request. 

(b) The Company shall deliver to each Significant Investor the items identified in Sections 4(a)(i), (ii) and
(iv) above. 
 (c) The foregoing financial statements shall be prepared on a consolidated basis if the Company then has
any subsidiaries. The financial statements delivered pursuant to clause (ii) shall be accompanied by a certificate of the chief financial officer of the Company stating that such statements have been prepared in accordance with generally
accepted accounting principles consistently applied (except as noted) and fairly present the financial condition and results of operations of the Company at the date thereof and for the periods covered thereby. 

4.5 Material Changes and Litigation. The Company shall promptly notify the Purchasers of any material adverse change in
the business, prospects, assets or condition, financial or otherwise, of the Company and of any litigation or governmental proceeding or investigation brought or, to the Company’s knowledge, threatened against the Company, or against any
officer, director, key employee or principal stockholder of the Company which, if adversely determined, would have a material adverse effect on the business, prospects, assets or condition (financial or otherwise) of the Company. 

4.6 Key Man Insurance. The Company shall maintain for a period of five years after the date hereof term life insurance
upon the life of Stephen T. Isaacs in the amount of $2,000,000, with the proceeds payable to the Company. 
 4.7
Agreements with Employees; Options. 
 (a) The Company shall require (i) all officers and employees of the
Company now or hereafter employed by the Company to enter into a Confidential Information and Invention Assignments and Non-Solicitation Agreement in the form attached as Exhibit G to the Purchase Agreement or such other form as may be approved by
the Board of Directors and (ii) all independent contractors utilized by the Company who have access to confidential or proprietary information of the Company to enter into confidential information and inventions assignment agreements. 

  
 -23- 

 (b) The Company agrees that it will not, without the prior written consent of
the holders of a majority of the Shares then outstanding, terminate, amend or waive any rights under any Confidential Information and Invention Assignments and Non-Solicitation Agreement or restricted stock agreement between the Company and any
officer. 
 (c) Unless otherwise approved by the Board of Directors of the Company and by a majority of the members of the
Board of Directors who are not employees of the Company or a Company Subsidiary, all options or restricted stock granted or issued by the Company shall become exercisable at the rate of 25% on the first anniversary of grant or issue and
2.083% per month thereafter over the subsequent three years so long as the holder continues to be an employee or consultant of the Company. 

4.8 Board of Directors. 

(a) The Company shall promptly reimburse in full each director of the Company who is not an employee of the Company for all of
his or her reasonable out-of-pocket expenses incurred in attending each meeting of the Board of Directors of the Company or any committee thereof. 

(b) The Board of Directors shall meet at least quarterly (either in person or by conference call) until the Company is
profitable (based on generally accepted accounting principles) for two consecutive quarters and thereafter the Board of Directors shall meet at least quarterly, unless otherwise agreed by a majority of the members of the Board of Directors. 

(c) The Board of Directors shall maintain compensation and audit committees consisting only of members of the Board of
Directors who are not employees of the Company or a Company Subsidiary. The Series B Directors and Series C Directors shall have the right to serve on the compensation committee. 

(d) The Company’s Charter shall at all times provide for the indemnification of the members of the Board of Directors to
the fullest extent provided by the law of the jurisdiction in which the Company is organized. In the event that the Company or any of its successors or assigns (i) consolidates with or merges into any other entity and shall not be the
continuing or surviving corporation in such consolidation or merger or (ii) transfers or conveys all or substantially all of its properties and assets to any entity, then, and in each such case, to the extent necessary, proper provision shall
be made so that the successors and assigns of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as contained in the Company’s Charter. 

4.9 Related Party Transactions. 

(a) The Company shall not enter into any agreement with any stockholder, officer or director of the Company, or any
“affiliate” of such persons (as such term is defined in the rules and regulations promulgated under the Securities Act), including without limitation any agreement or other arrangement providing for the

  
 -24- 

 
furnishing of services by, rental of real or personal property from, or otherwise requiring payments to, any such person or entity, without the consent of at least a majority of the members of
the Company’s Board of Directors having no interest in such agreement or arrangement. 
 (b) The approval of the Board
of Directors of the Company and a majority of the members of the Board of Directors who are not employees of the Company or a Company Subsidiary shall be required to (i) establish or increase the compensation of executive officers of the
Company or (ii) grant stock options to any officer of the Company. 
 4.10 Reservation of Common Stock. The
Company shall reserve and maintain a sufficient number of shares of Common Stock for issuance upon conversion of all of the outstanding Shares. 

4.11 International Investment and Trade in Services Survey Act. The Company shall use its best efforts to file on a
timely basis all reports required to be filed by it under 22 U.S.C. Section 3104, or any similar statute, relating to a foreign person’s direct or indirect investment in the Company. 

4.12 JJDC Observer Right. As long as JJDC owns not less than 50% of the shares of Series C Preferred purchased by JJDC
under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a representative of JJDC to attend all meetings of its Board of Directors in a nonvoting observer capacity (the
“Board Observer”) and, in this respect, shall give such Board Observer copies of all notices and other materials relating to such meetings that it provides to its directors; provided, however, that the Board Observer
shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such Board
Observer from any meeting or portion thereof if (i) access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or
(ii) a majority of the directors present at such meeting reasonably conclude that a real or potential conflict of interest exists or could exist between the Company and/or any of its existing or potential affiliates or business partners, and
the Board Observer or JJDC or any of their respective affiliates or business partners with regard to any subject matter to be discussed at such meeting or portion thereof. 

4.13 Pay-to-Play Protection. In the event that the Board of Directors determines to issue additional shares of Senior
Preferred or other series of Preferred Stock on or prior to December 31, 2014, the Purchasers may not, without the consent of JJDC, elect, or act by written consent, either in connection with such issuance or equity financing or thereafter
prior to December 31, 2014, to either (a) cause a mandatory conversion of any outstanding shares of Series C Preferred into Common Stock or Junior Preferred (as such term is defined in the Charter), or (b) amend the Charter to
adversely affect the rights of the holders of outstanding Series C Preferred with respect to their liquidation preference, conversion price (including anti-dilution protection), voting rights or redemption rights. 

  
 -25- 

 4.14 Publicity. The Company and the Purchasers (other than JJDC) shall
not, except as may be required by applicable laws or regulations, make any written or other public disclosure about JJDC without JJDC’s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. 

4.15 No Promotion. The Company agrees that it will not, and shall cause each of its subsidiaries to not, without the
prior written consent of Fidelity, use in advertising, publicity, or otherwise the name of Fidelity, or any Fidelity Purchaser, or any partner or employee of Fidelity or any Fidelity Purchaser, nor any trade name, trademark, trade device, service
mark, symbol or any abbreviation, contraction or simulation thereof owned by Fidelity, any Fidelity Purchaser or any of their respective affiliates. The Company further agrees that it shall obtain the written consent of Fidelity prior to the
Company’s or any of its subsidiaries’ issuance of any public statement detailing the purchase of Shares by Purchasers pursuant to this Agreement. The foregoing shall not prevent disclosure (a) as required by law (including, without
limitation, any rule or regulation promulgated by the Securities and Exchange Commission or any other competent regulatory authority), (b) to other stockholders or potential stockholders, or potential acquirors, or representatives of the
foregoing, that the Fidelity Purchasers hold equity securities in the Company or the amount thereof (such as in a capitalization table provided in diligence), or (c) to any legal, tax or accounting advisors of the Company; provided in the cases
of subsections (b) and (c), such persons or entities have signed confidentiality agreements containing, or are otherwise bound by confidentiality obligations at least as restrictive as those contained herein. 

4.16 Termination of Covenants. Other than the covenant contained in Section 4.10, all covenants of the Company
contained in this Section 4 shall terminate upon the earlier of the closing of a Company Sale or the closing of a Qualified IPO; provided, however, that the covenant contained in Section 4.13 shall expire on December 31, 2014. 

5. Confidentiality. Each Purchaser agrees that he, she or it will keep confidential and will not disclose, divulge or use for any
purpose, other than to monitor its investment in the Company, any Confidential Information, unless such Confidential Information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 5
by such Purchaser), (b) is or has been independently developed or conceived by the Purchaser without use of the Company’s Confidential Information or (c) is or has been made known or disclosed to the Purchaser by a third party without
a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that a Purchaser may disclose Confidential Information (i) to its attorneys, accountants, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company, (ii) to any prospective purchaser of any Shares from such Purchaser as long as such prospective purchaser agrees to be
bound by the provisions of this Section 5, (iii) to any Affiliated Party of such Purchaser or (iv) as may otherwise be required by law, provided that the Purchaser takes reasonable steps to minimize the extent of any such required
disclosure. 

  
 -26- 

 
Notwithstanding anything to the contrary, any Purchaser that is registered as an “investment company” under the Investment Company Act of 1940, as amended, shall be permitted to make
disclosures consistent with such Purchaser’s policies, procedures and practices. Notwithstanding the foregoing, such information shall not be deemed confidential for the purpose of enforcing this Agreement. 

6. Transfers of Rights; Calculation of Share Numbers. 

6.1 Transfer of Rights. This Agreement, and the rights and obligations of each Purchaser hereunder, may be assigned by
such Purchaser to (a) any person or entity to which at least 2,000,000 Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, recapitalizations and similar events occurring after the date of this Agreement)
are transferred by such Purchaser, or (b) to any Affiliated Party of such Purchaser, and, in each case, such transferee shall be deemed a “Purchaser” for purposes of this Agreement; provided that such assignment of rights shall be
contingent upon the transferee providing a written instrument to the Company notifying the Company of such transfer and assignment and agreeing in writing to be bound by the terms of this Agreement. Notwithstanding the foregoing, any person or
entity to which any Shares or Registrable Shares are transferred by a Purchaser, whether voluntarily or by operation of law, shall be bound by the obligations under Section 2.8 to the same extent as if such transferee were a Purchaser hereunder
and no Purchaser shall transfer any Shares or Registrable Shares unless the transferee provides a written instrument to the Company notifying the Company of such transfer and agreeing in writing to be bound by the terms of Section 2.8. 

6.2 Calculation of Share Numbers. In determining the number of Shares owned by a Purchaser for purposes of exercising
rights under this Agreement, (a) Shares owned by a Purchaser shall be deemed to include Shares which have been converted into Common Stock so long as such Common Stock is owned by such Purchaser and (b) all Shares held by affiliated
entities or persons shall be aggregated together (provided that no shares shall be attributed to more than one entity or person within any such group of affiliated entities or persons). 

7. General. 

7.1 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or
enforceability of any other provision of this Agreement. 
 7.2 Specific Performance. In addition to any and all other
remedies that may be available at law in the event of any breach of this Agreement, each Purchaser shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunctive or other equitable
relief as may be granted by a court of competent jurisdiction. 

  
 -27- 

 7.3 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware (without reference to the conflicts of law provisions thereof). 
 7.4
Notices. All notices, requests, consents and other communications under this Agreement shall be in writing and shall be deemed delivered (i) to a recipient in the United States, by registered or certified mail, return receipt requested,
postage prepaid or via a reputable nationwide overnight courier service guaranteeing next business day delivery when received, or (ii) to a recipient outside the United States, via a reputable international courier service guaranteeing
specified business day delivery when received, in each case to the intended recipient as set forth below: 
 If to the Company, at 626
Bancroft Way, #3C Berkeley, CA 94710, Attention: President, or at such other address as may have been furnished in writing by the Company to the other parties hereto, with a copy (which shall not constitute notice) to Cooley LLP, 3175 Hanover
Street, Palo Alto, CA 94304, Attention: Michael Tenta, Esq.; or 
 If to a Purchaser, at its address set forth on Exhibit A, or
at such other address as may have been furnished in writing by such Purchaser to the other parties hereto. 
 Any party may give any notice,
request, consent or other communication under this Agreement using any other means (including, without limitation, personal delivery, messenger service, telecopy, first class mail or electronic mail), but no such notice, request, consent or other
communication shall be deemed to have been duly given unless and until it is actually received by the party for whom it is intended. Any party may change the address to which notices, requests, consents or other communications hereunder are to be
delivered by giving the other parties notice in the manner set forth in this Section 7.4. 
 7.5 Complete
Agreement. This Agreement constitutes the entire agreement and understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter. 

7.6 Amendments and Waivers. This Agreement may be amended or terminated and the observance of any term of this Agreement
may be waived with respect to all parties to this Agreement (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company, the Purchasers who hold a majority of the then outstanding
shares of Common Stock issued or issuable upon conversion of the Series B Preferred and the Purchasers who hold a majority of the then outstanding shares of Common Stock issued or issuable upon conversion of the Series C Preferred and the Series D
Preferred, voting together as a single class on an as-converted to Common Stock basis; provided that any amendment, termination or waiver to the terms of Section 2 (or a defined term used therein) that occurs after the closing of the Initial
Public Offering shall instead require the written consent of the Company and Purchasers holding Registrable Shares representing a majority of the voting power of all Registrable Shares then held by all Purchasers. Notwithstanding the foregoing,
(a) this Agreement may not be amended or terminated and the observance of any term hereunder 

  
 -28- 

 
may not be waived with respect to any Purchaser without the written consent of such Purchaser unless such amendment, termination or waiver applies to all Purchasers in the same fashion (it being
agreed that a waiver of the provisions of Section 3 with respect to a particular transaction shall be deemed to apply to all Qualified Purchasers in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain
Qualified Purchasers may nonetheless, by agreement with the Company, purchase securities in such transaction), and (b) Exhibit A hereto may be amended by the Company from time to time in accordance with Section 2.2 of the Purchase
Agreement to add information regarding Additional Purchasers (as defined therein) without the consent of the other parties hereto, (c) no amendments may be made with respect to Section 4.12 or Section 4.13 without the written consent
of JJDC and (d) no amendments may be made with respect to the definition of “Major Investor,” Section 2.8, Section 3.2, Section 4.4, Section 4.15, Section 5 and Section 7.11 without the written consent of
Fidelity. The Company shall give prompt written notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination or waiver. Any amendment, termination or waiver
effected in accordance with this Section 7.6 shall be binding on all parties hereto, even if they do not execute such consent. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances,
shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 
 7.7
Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. 

7.8 Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts (including, in the
case of the Purchasers, Financing Signature Pages (as defined in the Purchase Agreement)), each of which shall be deemed to be an original, and all of which together shall constitute one and the same document. This Agreement (including the Financing
Signature Pages) may be executed by facsimile or .pdf signatures. 
 7.9 Section Headings and References. The section
headings are for the convenience of the parties and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties. Any reference in this agreement to a particular section or subsection shall refer to a section or
subsection of this Agreement, unless specified otherwise. 
 7.10 Additional Purchasers. Persons or entities that,
after the date hereof, purchase Shares pursuant to the Purchase Agreement and become Additional Purchasers thereunder may, with the prior written approval of the Company (but without the need for approval by any other party to this Agreement),
become parties to this Agreement by executing and delivering a Financing Signature Page, whereupon they shall be deemed “Purchasers” for all purposes of this Agreement. 

  
 -29- 

 7.11 Massachusetts Business Trust. 

(a) A copy of the Agreement and Declaration of Trust of each Fidelity Purchaser or any affiliate thereof is on file with the
Secretary of State of the Commonwealth of Massachusetts and notice is hereby given that this Agreement is executed on behalf of the trustees of such Fidelity Purchaser or any affiliate thereof as trustees and not individually and that the
obligations of this Agreement are not binding on any of the trustees, officers or stockholders of such Fidelity Purchaser or any affiliate thereof individually but are binding only upon such Fidelity Purchaser or any affiliate thereof and its assets
and property. 
 (b) A copy of the Agreement and Declaration of Trust of Janus Global Life Sciences Fund
(“Janus”), or any affiliate thereof is on file with the Secretary of State of the Commonwealth of Massachusetts and notice is hereby given that this Agreement is executed on behalf of the trustees of Janus or any affiliate thereof
as trustees and not individually and that the obligations of this Agreement are not binding on any of the trustees, officers or stockholders of Janus or any affiliate thereof individually but are binding only upon Janus or any affiliate thereof and
its assets and property. 
 7.12 Amendment and Restatement of Prior Agreement. Upon effectiveness of this
Agreement, the Prior Investor Rights Agreement shall be amended and restated to read in its entirety as set forth herein. 
 [Remainder of
page intentionally left blank.] 

  
 -30- 

 Executed as of the date first written above. 

 

			
	 COMPANY:

	
	ADURO BIOTECH, INC.
	
	 /s/ Stephen T. Isaacs

	By:		Stephen T. Isaacs
			President and Chief Executive Officer

 SIGNATURE PAGE TO 

ADURO BIOTECH, INC. AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT 

 
			
			INVESTOR:
		
			 For and on behalf of

MORNINGSIDE VENTURE (VI) INVESTMENTS LIMITED

		
	By:		 /s/ Louise Mary Garbarino/Jill Marie Franklin

		
	Name:		 Louise Mary Garbarino/Jill Marie Franklin

		
	Title:		 Authorized Signatures

 SIGNATURE PAGE TO 

ADURO BIOTECH, INC. AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT 

 
			
			INVESTOR:
		
			 For and on behalf of
 Ultimate Keen
Limited

		
	By:		 /s/ Hon Kit Bing/Li Choi Wan, Alice

		
	Name:		 Hon Kit Bing/Li Choi Wan, Alice

		
	Title:		 Authorized Signatures

 SIGNATURE PAGE TO 

ADURO BIOTECH, INC. AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT 

 
			
			INVESTOR:
		
	By:		 /s/ David Kanne

		
	Name:		David Kanne

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
			INVESTOR:
		
	By:		 /s/ Harry Kraemer

		
	Name:		Harry Kraemer

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENTS 

 
			
			INVESTOR:
		
	By:		 /s/ John E. Rogers

		
	Name:		John E. Rogers
		
	By:		 /s/ Lois A. Rogers

		
	Name:		Lois A. Rogers

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
			INVESTOR:
		
	By:		 /s/ John Foster

		
	Name:		John Foster

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENTS 

 
			
			INVESTOR:
		
	By:		 /s/ Barbara Gibian

		
	Name:		Barbara Gibian

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
			INVESTOR:
		
	By:		 /s/ Christopher Ray

		
	Name:		Christopher Ray

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
			INVESTOR:
		
	By:		 /s/ Thomas Gibian

		
	Name:		Thomas Gibian

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
			INVESTOR:
		
	By:		 /s/ Claes Glassell

		
	Name:		Claes Glassell

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. 
 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENTS 

 
			
			INVESTOR:
		
			TRITON HOLDINGS LLC
		
	By:		 /s/ Ross Haghighat

		
	Name:		 Ross Haghighat

		
	Title:		 Chief Executive Officer

 SIGNATURE PAGE TO 

ADURO BIOTECH, INC. AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT 

			
	INVESTOR:
	
	Fidelity Select Portfolios: Biotechnology Portfolio

 
					
			
			By:		 /s/ Stacie M. Smith

			Name:		Stacie M. Smith
			Title:		Authorized Signatory

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

			
	INVESTOR:
	
	Fidelity Advisor Series VII: Fidelity
Advisor Biotechnology Fund

 
					
			
			By:		 /s/ Stacie M. Smith

			Name:		Stacie M. Smith
			Title:		Authorized Signatory

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

			
	INVESTOR:
	
	Fidelity Securities Fund: Fidelity OTC Portfolio

 
					
			
			By:		 /s/ Stacie M. Smith

			Name:		Stacie M. Smith
			Title:		Authorized Signatory

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	Foresite Capital Fund II, LP
	
	By: Foresight Capital Management II, LLC
	Its: General Partner

 
					
			
			By:		 /s/ Dennis D. Ryan

			Name:		Dennis D. Ryan
			Title:		CFO

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	Janus Global Life Sciences Fund
		
	By:		 /s/ Andrew Acker

	Name:		Andrew Acker
	Title:		Portfolio Manager

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	 By: OrbiMed Capital GP V LLC
 Its:
General Partner

 
					
			
			By:		OrbiMed Advisors LLC
			Its:		Managing Member
			
			By:		 /s/ W. Carter Neild

			Name:		W. Carter Neild
			Title:		Member

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	Jennison Global Healthcare Master Fund, Ltd.
	
	By: Jennison Associates LLC
	Its:		Investment Manager of Jennison Global Healthcare Master Fund, Ltd.

  

			
	By:		 /s/ David Chan

	Name:		David Chan
	Title:		Managing Director

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	Clough Investment Partners I, L.P.
	
	By: Clough Capital Partners L.P.,
	Its: Investment Manager

  

			
	By:		 /s/ John A. Ritacco, Jr.

	Name:		John A. Ritacco, Jr.
	Title:		Chief Financial Officer

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	Clough Investment Partners II, L.P.
	
	By: Clough Capital Partners L.P.,
	Its: Investment Manager

  

			
	By:		 /s/ John A. Ritacco, Jr.

	Name:		John A. Ritacco, Jr.
	Title:		Chief Financial Officer

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

			
	INVESTOR:
	
	Clough Offshore Fund, Ltd.
	
	By: Clough Capital Partners L.P.,
	Its: Investment Manager

  

			
	By:		 /s/ John A. Ritacco, Jr.

	Name:		John A. Ritacco, Jr.
	Title:		Chief Financial Officer

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	Clough Offshore Fund (QP), Ltd.
		
	By:		Clough Capital Partners L.P.,
	Its:		Investment Manager

  

			
	By:		 /s/ John A. Ritacco, Jr.

	Name:		John A. Ritacco, Jr.
	Title:		Chief Financial Officer

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	 Franklin Strategic Series-Franklin

Biotechnology Discovery Fund

		
	By:		Franklin Advisers, Inc.
	Its:		Investment Manager

  

			
	By:		 /s/ Evan McCulloch

	Name:		Evan McCulloch
	Title:		Vice President

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	 Franklin Templeton Investment Funds-

Franklin Biotechnology Discovery Fund

		
	By:		Franklin Advisers, Inc.
	Its:		Investment Manager

  

			
	By:		 /s/ Evan McCulloch

	Name:		Evan McCulloch
	Title:		Vice President

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	Rock Springs Capital Master Fund LP
		
	By:		Rock Springs GP LLC
	Its:		General Partner

  

			
	By:		 /s/ Graham McPhail

	Name:		Graham McPhail
	Title:		 Managing Director
 Rock Springs
Capital

			650 S. Exeter St., Suite 1070
			Baltimore, MD 21202

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	Leerink Holdings LLC

  

			
	By:		 /s/ Timothy A. G. Gerhold

	Name:		Timothy A. G. Gerhold
	Title:		General Counsel

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
	
	Leerink Swann Co-Investment Fund, LLC

 
					
			
			By:		 /s/ Jeffrey A. Leerink

			Name:		Jeffrey A. Leerink
			Title:		Manager

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 
			
			INVESTOR:
		
			MOSSROCK CAPITAL, LLC
		
	By:		 /s/ Thomas Malley

	Name:		Thomas Malley
	Title:		President

 SIGNATURE PAGE TO 

ADURO BIOTECH, INC. AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT 

 
			
	INVESTOR:
		
	By:		 /s/ Alan Auerbach

	Name:		Alan Auerbach

 SIGNATURE PAGE TO ADURO
BIOTECH, INC. INVESTOR RIGHTS AGREEMENT 

 Exhibit A 

List of Purchasers 
 Name and Address

 David R. Fischell 
 Hearst Revocable Trust 3/3/89 

Christopher Ray 
 John Foster 

John E. and Lois A. Rogers 
 Stephen Isaacs 

Triton Holdings LLC 
 David Clayton and Gayle DeKellis Trust

 The Crocker Family Trust as amended on 4/1/2002 
 David
Kanne 
 Thomas R. Gibian 
 Morningside Venture (VI)
Investments Limited 
 Johnson & Johnson Development Corporation 

Harry Kraemer 
 Barbara Gibian 

Ultimate Keen Limited 
 Mag & Co fbo Fidelity Select
Portfolios: Biotechnology Portfolio 
 Bangle & Co fbo Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund 

  
 A - 1 

 Booth & Co fbo Fidelity Securities 

Fund: Fidelity OTC Portfolio 
 Foresite Capital Fund II, LP 

BUOYBREEZE + CO 
 OrbiMed Private Investments V, LP 

Jennison Global Healthcare Master 
 Fund, Ltd. 

Clough Investment Partners I, L.P. 
 Clough Investment Partners
II, L.P. 
 Clough Offshore Fund, Ltd. 
 Clough Offshore Fund
(QP), Ltd. 
 Hare & Co FBO/Franklin Strategic 

Series – Franklin Biotechnology 
 Discovery Fund 

Egger & Co FBO/Franklin Templeton 
 Investment Funds
– Franklin 
 Biotechnology Discovery Fund 
 Rock Springs
Capital Master Fund 
 LP 
 Leerink Holdings, LLC 

Leerink Swann Co-Investment Fund, 
 LLC 

Mossrock Capital, LLC 
 Alan Auerbach 

  
 A - 2EX-10.1

 Exhibit 10.1 

ONCOLOGIC, INC. 
 2000
LONG-TERM INCENTIVE PLAN 
 ARTICLE 1. ESTABLISHMENT AND PURPOSE 

1.1 Establishment. Oncologic, Inc., a California corporation, hereby establishes the Oncologic, Inc. 2000 Long-Term Incentive Plan, as
set forth in this document. 
 1.2 Purpose. The purposes of the Plan are to attract able persons to enter the employ of the Company,
to encourage Employees to remain in the employ of the Company and to provide motivation to Employees to put forth maximum efforts toward the continued growth, profitability and success of the Company, by providing incentives to such persons through
the ownership and performance of the Common Stock of Oncologic. A further purpose of the Plan is to provide a means through which the Company may attract able persons to become directors, consultants and independent contractors of the Company and to
provide such individuals with incentive and reward opportunities. Toward these objectives, Awards may be granted under the Plan to Employees, Outside Directors and Consultants on the terms and subject to the conditions set forth in the Plan. 

1.3 Effectiveness. The Plan shall become effective as of December 9, 2000, the date of its adoption by the Board, provided it is
duly approved by the holders of at least a majority of the shares of Common Stock present or represented and entitled to vote at a meeting of the stockholders of Oncologic duly held in accordance with applicable law within twelve months after the
date of adoption of the Plan by the Board. If the Plan is not so approved, the Plan shall terminate and any Award granted hereunder shall be null and void. 

ARTICLE 2. DEFINITIONS 

2.1 Affiliate. “Affiliate” means a “parent corporation” or a “subsidiary corporation” of Oncologic, as
those terms are defined in Section 424(e) and (f) of the Code. 
 2.2 Award. “Award” means any Option, SAR,
Restricted Stock, Dividend Equivalent or Other Incentive Award granted under the Plan, whether singly, in combination or in tandem, to a Participant. 

2.3 Award Agreement. “Award Agreement” means a written agreement between Oncologic and a Participant that sets forth the
terms, conditions, restrictions and/or limitations applicable to an Award. 
 2.4 Board. “Board” means the Board of
Directors of Oncologic. 
 2.5 Code. “Code” means the Internal Revenue Code of 1986, as amended from time to time,
including regulations thereunder and successor provisions and regulations thereto. 

 2.6 Committee. “Committee” means the Compensation Committee of the Board, or
such other Committee of the Board as may be designated by the Board to administer the Plan; provided, however, that from and after such time as Oncologic registers a class of equity securities under Section 12 of the Exchange Act, the Committee
shall consist of two or members of the Board, all of whom are both a “Non-Employee Director” within the meaning of Rule 16b-3 under the Exchange Act and an “outside director” within the meaning of the definition of such term as
contained in Treasury Regulation Section 1.162-27(e)(3) interpreting Section 162(m) of the Code, or any successor definitions adopted. The members of the Committee shall be appointed from time to time by, and shall serve at the discretion
of, the Board. 
 2.7 Common Stock. “Common Stock” means the Common Stock, par value $0.01 per share, of Oncologic or any
stock or other securities of Oncologic hereafter issued or issuable in substitution or exchange for the Common Stock. 
 2.8 Company.
“Company” means Oncologic and its Affiliates. 
 2.9 Consultant. “Consultant” means any individual who performs
services for and is treated by Oncologic or an Affiliate as an independent contractor for employment tax purposes, but does not include an Outside Director. 

2.10 Dividend Equivalents. “Dividend Equivalents” means an Award granted to a Participant pursuant to Article 10. 

2.11 Effective Date. “Effective Date” means the date an Award is determined to be effective by the Board upon the grant of
such Award. 
 2.12 Employee. “Employee” means any person treated as an employee by Oncologic or an Affiliate.
“Employee” shall not include a Consultant or an Outside Director. 
 2.13 Exchange Act. “Exchange Act” means the
Securities Exchange Act of 1934, as amended. 
 2.14 Fair Market Value. “Fair Market Value” means the closing sale price
per share on the date in question, or if no reported sale on such date, on the last preceding date on which any reported sale occurred of the Common Stock on the Nasdaq National Market or any national stock exchange or, if the Common Stock is not
traded publicly, the fair market value per share as determined in good faith by the Board. 
 2.15 Incentive Stock Option.
“Incentive Stock Option” means an Option that is intended to meet the requirements of Section 422(b) of the Code. 
 2.16
Nonqualified Stock Option. “Nonqualified Stock Option” means an Option that is not intended to meet the requirements of Section 422(b) of the Code. 

  
 -2- 

 2.17 Oncologic. “Oncologic” means Oncologic, Inc., a California corporation, and
any successor thereto. 
 2.18 Option. “Option” means an option to purchase shares of Common Stock granted to a Participant
pursuant to Article 7, and includes both Incentive Stock Options and Nonqualified Stock Options. 
 2.19 Other Incentive Award.
“Other Incentive Award” means an Award granted to a Participant pursuant to Article 11. 
 2.20 Outside Director.
“Outside Director” means an individual duly elected or chosen as a director or advisory director of Oncologic who is not also an Employee. 

2.21 Participant. “Participant” means any Employee, Outside Director or Consultant to whom an Award has been granted under
the Plan. 
 2.22 Plan. “Plan” means this Oncologic, Inc. 2000 Long-Term Incentive Plan. 

2.23 Restricted Stock. “Restricted Stock” means an Award of shares of Common Stock granted to a Participant pursuant to, and
with such restrictions as are imposed under, Article 9. Restricted Stock shall constitute issued and outstanding shares of Common Stock for all corporate purposes. 

2.24 SARs. “SARs” means an Award of stock appreciation rights granted to a Participant pursuant to Article 8. 

2.25 1933 Act. “1933 Act” means the Securities Act of 1933, as amended. 

ARTICLE 3. PLAN ADMINISTRATION 

3.1 Plan Administrator. The Plan shall be administered by the Board. The Board may delegate responsibility for administration of the
Plan to a Committee appointed by and serving at the pleasure of the Board, under such terms and conditions as the Board shall determine. If the Board shall delegate responsibility for administration of the Plan to a Committee pursuant to this
Section, any reference to the Board in the Plan (other than such references in Article 13) shall be construed as a reference to the Committee. 

3.2 Authority of Administrator. The Board shall have total and exclusive responsibility to control, operate, manage and administer the
Plan in accordance with its terms. The Board shall have all the authority that may be necessary or helpful to enable it to discharge its responsibilities with respect to the Plan. Without limiting the generality of the preceding sentence, the Board
shall have the exclusive right to: (i) interpret the Plan and the Award Agreements 

  
 -3- 

 
executed hereunder; (ii) determine eligibility for participation in the Plan; (iii) decide all questions concerning eligibility for, and the amount of, Awards payable under the Plan;
(iv) construe any ambiguous provision of the Plan or any Award Agreement; (v) prescribe the form of the Award Agreements embodying Awards granted under the Plan; (vi) correct any defect, supply any omission or reconcile any
inconsistency in the Plan or any Award Agreement; (vii) issue administrative guidelines as an aid to administer the Plan and make changes in such guidelines as it from time to time deems proper; (viii) make regulations for carrying out the
Plan and make changes in such regulations as it from time to time deems proper; (ix) determine whether Awards should be granted singly, in combination or in tandem; (x) to the extent permitted under the Plan, grant waivers of Plan terms,
conditions, restrictions and limitations; (xi) accelerate the exercise, vesting or payment of an Award when such action or actions would be in the best interests of the Company; (xii) grant Awards in replacement of Awards previously
granted under the Plan or any other employee benefit plan of the Company; and (xiii) take any and all other actions it deems necessary or advisable for the proper operation or administration of the Plan. 

3.3 Discretionary Authority. The Board shall have full discretionary authority in all matters related to the discharge of its
responsibilities and the exercise of its authority under the Plan, including, without limitation, its construction of the terms of the Plan and its determination of eligibility for participation and Awards under the Plan. The decisions of the Board
and its actions with respect to the Plan shall be final, conclusive and binding on all persons having or claiming to have any right or interest in or under the Plan, including Participants and their respective estates, beneficiaries and legal
representatives. 
 3.4 Liability; Indemnification. No member of the Board nor any person to whom authority has been delegated, shall
be personally liable for any action, interpretation or determination made in good faith with respect to the Plan or Awards granted hereunder, and each member of the Board (or delegatee of the Board) shall be fully indemnified and protected by
Oncologic with respect to any liability he or she may incur with respect to any such action, interpretation or determination, to the extent permitted by applicable law. 

3.5 Public Company. From and after such time as Oncologic registers a class of equity securities under Section 12 of the Exchange
Act, it is intended that this Plan be administered in accordance with the disinterested administration requirements of Rule 16b-3 promulgated by the Securities and Exchange Commission, or any successor rule thereto. With respect to persons subject
to Section 16 of the Exchange Act, if any, transactions under the Plan are intended to comply with the applicable conditions of Rule 16b-3, or any successor rule thereto. Notwithstanding the above, it shall be the responsibility of such
persons, not the Company, the Board, or the Committee, to comply with the requirements of Section 16 of the Exchange Act. 
 ARTICLE
4. ELIGIBILITY 

  
 -4- 

 All Employees, Outside Directors and Consultants are eligible to participate in the Plan. The
Board shall recommend, from time to time, Participants from those Employees and Consultants, who, in the opinion of the Board, can further the Plan purposes. Once a Participant is recommended for an Award by the Board, the Board shall determine the
type and size of Award to be granted to the Participant and shall establish in the related Award Agreement the terms, conditions, restrictions and/or limitations applicable to the Award, in addition to those set forth in the Plan and the
administrative rules and regulations, if any, established by the Board. 
 ARTICLE 5. FORM OF AWARDS 

Awards may, at the Board’s sole discretion, be granted under the Plan in the form of Options pursuant to Article 7, SARs pursuant to
Article 8, Restricted Stock pursuant to Article 9, Dividend Equivalents pursuant to Article 10, Other Incentive Awards pursuant to Article 11 or a combination thereof. All Awards shall be subject to the terms, conditions, restrictions and
limitations of the Plan. The Board may, in its sole judgment, subject any Award to such other terms, conditions, restrictions and/or limitations (including, but not limited to, the time and conditions of exercise, vesting or payment of an Award and
restrictions on transferability of any shares of Common Stock issued or delivered pursuant to an Award), provided they are not inconsistent with the terms of the Plan. Awards under a particular Article of the Plan need not be uniform, and Awards
under two or more Articles of the Plan may be combined into a single Award Agreement. Any combination of Awards may be granted at one time and on more than one occasion to the same Participant. 

ARTICLE 6. SHARES SUBJECT TO THE PLAN 

6.1 Available Shares. The maximum number of shares of Common Stock that shall be available for grant of Awards under the Plan shall not
exceed a total of 2,446,200, subject to adjustment as provided in Sections 6.2 and 6.3. Shares of Common Stock issued pursuant to the Plan may be shares of original issuance or treasury shares or a combination of the foregoing, as the Board, in its
discretion, shall from time to time determine. 
 6.2 Adjustments for Recapitalizations and Reorganizations. 

(a) The shares with respect to which Awards may be granted under the Plan are shares of Common Stock as presently constituted,
but if, and whenever, prior to the expiration or satisfaction of an Award theretofore granted, Oncologic shall effect a subdivision or consolidation of shares of Common Stock or the payment of a stock dividend on Common Stock without receipt of
consideration by Oncologic, the number of shares of Common Stock with respect to which such Award may thereafter be exercised or satisfied, as applicable, (i) in the event of an increase in the number of outstanding shares shall be
proportionately increased, and the exercise price per share shall be proportionately reduced, and (ii) in the event of a reduction in the number of outstanding 

  
 -5- 

 
shares shall be proportionately reduced, and the exercise price per share shall be proportionately increased. 

(b) If Oncologic recapitalizes or otherwise changes its capital structure, thereafter upon any exercise or satisfaction, as
applicable, of an Award theretofore granted the Participant shall be entitled to (or entitled to purchase, if applicable) under such Award, in lieu of the number of shares of Common Stock then covered by such Award, the number and class of shares of
stock or other securities to which the Participant would have been entitled pursuant to the terms of the recapitalization if, immediately prior to such recapitalization, the Participant had been the holder of record of the number of shares of Common
Stock then covered by such Award. 
 (c) In the event of changes in the outstanding Common Stock by reason of a Corporate
Transaction (as hereinafter defined), recapitalization, reorganization, merger, consolidation, combination, separation (including a spin-off or other distribution of stock or property), exchange, or other relevant change in capitalization occurring
after the date of grant of any Award and not otherwise provided for by this Section 6.2, any outstanding Awards and any Award Agreements evidencing such Awards shall be subject to adjustment by the Board at its discretion as to the number,
price and kind of shares or other consideration subject to, and other terms of, such Awards to reflect such changes in the outstanding Common Stock. 

(d) In the event of any changes in the outstanding Common Stock provided for in this Section 6.2, the aggregate number of
shares available for grant of Awards under the Plan may be equitably adjusted by the Board, whose determination shall be conclusive. Any adjustment provided for in this Section 6.2 shall be subject to any required stockholder action. 

6.3 Adjustments for Awards. The Board shall have full discretion to determine the manner in which shares of Common Stock available for
grant of Awards under the Plan are counted. Without limiting the discretion of the Board under this Section 6.3, unless otherwise determined by the Board, the following rules shall apply for the purpose of determining the number of shares of
Common Stock available for grant of Awards under the Plan: 
 (a) Options and Restricted Stock. The grant of Options
and Restricted Stock shall reduce the number of shares available for grant of Awards under the Plan by the number of shares subject to such Award. 

(b) SARs. The grant of SARs shall not affect the number of shares available for grant of Awards under the Plan. 

(c) Dividend Equivalents. The grant of Dividend Equivalents shall not affect the number of shares available for grant of
Awards under the Plan, but such number of 

  
 -6- 

 
shares shall be reduced by any shares issued in payment or settlement of Dividend Equivalents. 

(d) Other Incentive Awards. The grant of an Other Incentive Award in the form of Common Stock or that may be paid or
settled only in Common Stock shall reduce the number of shares available for grant of Awards under the Plan by the number of shares subject to such Award. The grant of an Other Incentive Award that may be paid or settled only for cash shall not
affect the number of shares available for grant of Awards under the Plan. The grant of an Other Incentive Award that may be paid or settled in either Common Stock or cash shall reduce the number of shares available for grant of Awards under the Plan
by the number of shares subject to such Award. 
 (e) Termination. If any Award referred to in paragraphs (a) and
(d) above (other than an Other Incentive Award that may be paid or settled only for cash) is canceled or forfeited, or terminates, expires or lapses, for any reason (other than the termination of a Related Option (as defined in
Section 8.1) upon exercise of its corresponding SARs), the shares then subject to such Award shall again be available for grant of Awards under the Plan. 

(f) Payment of Exercise Price and Withholding Taxes. If previously acquired shares of Common Stock are used to pay the
exercise price of an Award, or shares of Common Stock that would be acquired upon exercise of an Award are withheld to pay the exercise price of such Award, the number of shares available for grant of Awards under the Plan other than Incentive Stock
Options shall be increased by the number of shares delivered or withheld as payment of such exercise price. If previously acquired shares of Common Stock are used to pay withholding taxes payable upon exercise, vesting or payment of an Award, or
shares of Common Stock that would be acquired upon exercise, vesting or payment of an Award are withheld to pay withholding taxes payable upon exercise, vesting or payment of such Award, the number of shares available for grant of Awards under the
Plan other than Incentive Stock Options shall be increased by the number of shares delivered or withheld as payment of such withholding taxes. 

ARTICLE 7. OPTIONS 

7.1 General. Awards may be granted to Employees, Outside Directors and Consultants in the form of Options. For Employees, Options
granted under the Plan may be Incentive Stock Options or Nonqualified Stock Options, or a combination of both. For Outside Directors and Consultants, Options granted under the Plan may only be in the form of Nonqualified Stock Options. 

7.2 Terms and Conditions of Options. An Option shall be exercisable in whole or in such installments and at such times as may be
determined by the Board. The price at which a 

  
 -7- 

 
share of Common Stock may be purchased upon exercise of a Nonqualified Stock Option shall be determined by the Board, but such exercise price shall not be less than 85% (except that in the case
of any person who owns stock possessing more than ten percent of the total combined voting power of all classes of stock of Oncologic or an Affiliate, not less than 110%) of the Fair Market Value per share of Common Stock on the Effective Date of
the Option’s grant. Except as otherwise provided in Section 7.3, the term of each Option shall be as specified by the Board; provided, however, that no Option shall be exercisable later than 10 years from the Effective Date of the
Option’s grant. In no event shall the Board impose a vesting schedule upon any Option granted to an Employee (or any shares of Restricted Stock received upon exercise of such Option) that is more restrictive than 20% per year with the
initial vesting date to occur no later than the first anniversary of the Option’s grant date; however, such limitation shall not be applicable to any Option grants made to individuals who are Outside Directors, Consultants or officers of the
Company. 
 7.3 Restrictions Relating to Incentive Stock Options. Options granted in the form of Incentive Stock Options shall, in
addition to being subject to the terms and conditions of Section 7.2, comply with Section 422(b) of the Code. Accordingly, no Incentive Stock Options shall be granted later than 10 years from the date of adoption of the Plan by the Board.
In addition, no Incentive Stock Option shall be exercisable after the expiration of ten years from the effective date of the Stock Option’s grant. To the extent that the aggregate Fair Market Value (determined at the time the respective
Incentive Stock Option is granted) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by an individual during any calendar year under all incentive stock option plans of Oncologic and its Affiliates
exceeds $100,000, such excess Incentive Stock Options shall be treated as options which do not constitute Incentive Stock Options. The price at which a share of Common Stock may be purchased upon exercise of an Incentive Stock Option shall be
determined by the Board, but such exercise price shall not be less than 100% of the Fair Market Value of a share of Common Stock on the Effective Date of the Option’s grant. No Incentive Stock Option shall be granted to an Employee under the
Plan if, at the time such Option is granted, such Employee owns stock possessing more than 10% of the total combined voting power of all classes of stock of Oncologic or an Affiliate, within the meaning of Section 422(b)(6) of the Code, unless
(i) on the Effective Date of grant of such Option, the exercise price of such Option is at least 110% of the Fair Market Value of the Common Stock subject to the Option and (ii) such Option by its terms is not exercisable after the
expiration of five years from the Effective Date of the Option’s grant. 
 7.4 Additional Terms and Conditions. The Board may
subject any Award of an Option to such other terms, conditions, restrictions and/or limitations as it determines are necessary or appropriate, provided they are not inconsistent with the Plan. 

  
 -8- 

 7.5 Exercise of Options. Subject to the terms and conditions of the Plan, Options shall be
exercised by the delivery of a written notice of exercise to Oncologic, setting forth the number of shares of Common Stock with respect to which the Option is to be exercised, accompanied by full payment for such shares. 

Upon exercise of an Option, the exercise price of the Option shall be payable to Oncologic in full either: (a) in cash or an equivalent
acceptable to the Board or (b) in the discretion of the Board and in accordance with any applicable administrative guidelines established by the Board, by (i) tendering previously acquired nonforfeitable, unrestricted shares of Common
Stock that have been held by the Participant for at least six months and that have an aggregate Fair Market Value at the time of exercise equal to the total exercise price or (c) a combination of the forms of payment specified in clauses
(a) or (b)(i) above. 
 In addition, the Board, in its sole and absolute discretion, may approve the extension of a loan to an optionee
who is an Employee to assist the optionee in paying the exercise price of an Option; provided, however, that no such loan shall be for an amount greater than the excess of (i) the exercise price of the shares of Common Stock issuable upon
exercise of the Option over (ii) the par value of such shares of Common Stock. Any such loan will be made on such terms and conditions as the Board shall deem to be appropriate and in accordance with applicable law. 

From and after such time as Oncologic registers the Common Stock under Section 12 of the Exchange Act, payment of the exercise price of
an Option may also be made, in the discretion of the Board, by delivery to Oncologic or its designated agent of an executed irrevocable option exercise form together with irrevocable instructions to a broker-dealer to sell or margin a sufficient
portion of the shares with respect to which the Option is exercised and deliver the sale or margin loan proceeds directly to Oncologic to pay for the exercise price and any required withholding taxes. 

In addition, any grant of a Nonqualified Stock Option under the Plan may provide that payment of the exercise price of the Nonqualified Stock
Option may also be made in whole or in part in the form of shares of Restricted Stock or other shares of Common Stock that are subject to risk of forfeiture or restrictions on transfer, provided that such shares have been held by the Participant for
at least six months. Unless otherwise determined by the Board at the time of grant of such Nonqualified Stock Option, whenever the exercise price of such Nonqualified Stock Option is paid in whole or in part by means of the form of consideration
specified in the immediately preceding sentence, the shares of Common Stock received by the Participant upon the exercise of such Option shall be subject to the same risk of forfeiture and restrictions on transfer as those that applied to the
consideration surrendered by the Participant. However, the risk of forfeiture and restrictions on transfer shall apply only to the same number of shares of Common Stock received by the Participant upon exercise as applied to the forfeitable or
restricted Common Stock surrendered by the Participant in payment of the exercise price. 

  
 -9- 

 As soon as reasonably practicable after receipt of written notification of exercise of an Option
and full payment of the exercise price and any required withholding taxes, Oncologic shall deliver to the Participant, in the Participant’s name, a stock certificate or certificates in an appropriate amount based upon the number of shares of
Common Stock purchased under the Option. 
 7.6 Termination of Service. Each Award Agreement embodying the Award of an Option shall
set forth the extent to which the Participant shall have the right to exercise the Option following termination of the Participant’s employment or service with the Company. Such provisions shall be determined in the sole discretion of the
Board, need not be uniform among all Options granted under the Plan and may reflect distinctions based on the reasons for termination of employment or service. Subject to the last paragraph of this Section 7.6, in the event that a
Participant’s Award Agreement embodying the Award of an Option does not set forth such termination provisions, the following termination provisions shall apply with respect to such Award. 

(a) Death or Disability. If the employment or service of a Participant shall terminate by reason of death or permanent
and total disability (within the meaning of Section 22(e)(3) of the Code), outstanding Options held by the Participant may be exercised, to the extent then vested, no more than one year from the date of such termination, unless the Options, by
their terms, expire earlier. 
 (b) Other Termination. If the employment or service of a Participant shall terminate
for any reason other than the reasons set forth in paragraph (a) above or (c) below, whether on a voluntary or involuntary basis, outstanding Options held by the Participant may be exercised, to the extent then vested, no more than three
months from the date of such termination, unless the Options, by their terms, expire earlier. 
 (c) Termination for
Cause. Notwithstanding paragraphs (a) and (b) above, if the employment or service of a Participant shall be terminated by reason of (i) such Participant’s fraud or dishonesty, (ii) any unauthorized use or disclosure by
such Participant of any confidential information or trade secrets of the Company, (iii) any unauthorized disclosure by such Participant of the amount of any Award under this Plan, (iv) the performance by such Participant of other acts
detrimental to the Company, or (v) without limiting the foregoing, “cause” as defined in any then-applicable employment or service agreement between the Company and such Participant, then in any such case all outstanding Options held
by the Participant shall immediately be forfeited to the Company and no additional exercise period shall be allowed, regardless of the vested status of the Options. 

Notwithstanding anything in this Section 7.6 to the contrary, in no event shall an Award Agreement provide that a Participant has
(i) less than six months to exercise an Option in the event of such Participant’s termination of employment or service on account of death or 

  
 -10- 

 
permanent and total disability (within the meaning of Section 22(e)(3) of the Code), or (ii) less than 30 days to exercise an Option in the event of the involuntary termination of
Participant’s employment or service without cause. 
 7.7 Maximum Option Grants. Any provision of this Plan to the contrary
notwithstanding, from and after such time as Oncologic registers a class of equity securities under Section 12 of the Exchange Act, the maximum number of shares of Common Stock for which Options and SARs may be granted under the Plan to any one
Employee during a calendar year is 500,000. 
 ARTICLE 8. SARs 

8.1 General. The Board may from time to time grant SARs in conjunction with all or any portion of any Option (the “Related
Option”) either (i) at the time of the initial Option grant (not including any subsequent modification that may be treated as a new grant of an Incentive Stock Option for purposes of Section 424(h) of the Code) or (ii) with
respect to Nonqualified Stock Options, at any time after the initial Option grant while the Nonqualified Stock Option is still outstanding. SARs shall not be granted other than in conjunction with an Option granted hereunder. 

8.2 Terms and Conditions. SARs granted hereunder shall comply with the following conditions and also with the terms of the Award
Agreement governing the Related Option: 
 (a) The SAR shall expire no later than the expiration of the Related Option. 

(b) Upon the exercise of an SAR, the Participant shall be entitled to receive from Oncologic or the appropriate Affiliate in
cash an amount equal to the excess of the aggregate Fair Market Value of the shares of Common Stock with respect to which the SAR is then being exercised (determined as of the date of such exercise) over the aggregate purchase price of such shares
as provided in the Related Option. 
 (c) SARs shall be exercisable (i) only at such time or times and only to the
extent that the Related Option shall be exercisable, (ii) only when the Fair Market Value of the shares subject to the Related Option exceeds the purchase price of the shares as provided in the Related Option, and (iii) only upon surrender
of the Related Option or any portion thereof with respect to the shares for which the SARs are then being exercised. 
 (d)
Upon the exercise of an SAR, the Related Option shall be deemed to have been terminated to the extent of the number of shares of Common Stock with respect to which such SARs are exercised. Upon the exercise or termination of the Related Option, the
SARs with respect to such Related Option shall be deemed to have been terminated to 

  
 -11- 

 
the extent of the number of shares of Common Stock with respect to which the Related Option was so exercised or terminated. 

8.3 Exercise of SARs. Each exercise of SARs, or a portion thereof, shall be evidenced by a notice in writing to Oncologic. 

ARTICLE 9. RESTRICTED STOCK 

9.1 General. Awards may be granted to Employees and Consultants in the form of Restricted Stock. Restricted Stock shall be awarded in
such numbers and at such times as the Board shall determine. 
 9.2 Restriction Period. At the time an Award of Restricted Stock is
granted, the Board shall establish a period of time (the “Restriction Period”) applicable to such Restricted Stock. Each Award of Restricted Stock may have a different Restriction Period, in the discretion of the Board. The Restriction
Period applicable to a particular Award of Restricted Stock shall not be changed except as permitted by Section 6.2, Section 9.3 or Article 12. 

9.3 Other Terms and Conditions. Restricted Stock awarded to a Participant under the Plan shall be represented by a stock certificate
registered in the name of the Participant or, at the option of Oncologic, in the name of a nominee of Oncologic. Subject to the terms and conditions of the Award Agreement, a Participant to whom Restricted Stock has been awarded shall have the right
to receive dividends thereon during the Restriction Period, to vote the Restricted Stock and to enjoy all other stockholder rights with respect thereto, except that (i) the Participant shall not be entitled to possession of the stock
certificate representing the Restricted Stock until the Restriction Period shall have expired, (ii) Oncologic shall retain custody of the Restricted Stock during the Restriction Period, (iii) the Participant may not sell, transfer, pledge,
exchange, hypothecate or otherwise dispose of the Restricted Stock during the Restriction Period and (iv) a breach of the terms and conditions established by the Board pursuant to the Award of the Restricted Stock shall cause a forfeiture of
the Restricted Stock. At the time of an Award of Restricted Stock, the Board may, in its sole discretion, prescribe additional terms, conditions, restrictions and/or limitations applicable to the Restricted Stock, including, but not limited to,
rules pertaining to the termination of employment or service (by reason of death, permanent and total disability, or otherwise) of a Participant prior to expiration of the Restriction Period. 

9.4 Payment for Restricted Stock. A Participant shall not be required to make any payment for Restricted Stock awarded to the
Participant, except to the extent otherwise required by the Board or by applicable law. In the event payment is required in order to receive Restricted Stock, then the purchase price per share shall not be less than: 

(a) in the case of any Participant who owns stock possessing 10% or less of the total combined voting power or value of all
classes of stock of Oncologic or an 

  
 -12- 

 
Affiliate, 85% of the Fair Market Value per share of Common Stock at the time of the Award or at the time the purchase is consummated; and 

(b) in the case of any Participant who owns stock possessing more than 10% of the total combined voting power or value of all
classes of stock of Oncologic or an Affiliate, 100% of the Fair Market Value per share of Common Stock either at the time of the Award or at the time the purchase is consummated. 

9.5 Miscellaneous. Nothing in this Article 9 shall prohibit the exchange of shares of Restricted Stock issued under the Plan pursuant
to a plan of reorganization for stock or securities of Oncologic or another corporation that is a party to the reorganization, but the stock or securities so received for shares of Restricted Stock shall, except as provided in Section 6.2 or
Article 12, become subject to the restrictions applicable to the Award of such Restricted Stock. Any shares of stock received as a result of a stock split or stock dividend with respect to shares of Restricted Stock shall also become subject to the
restrictions applicable to the Award of such Restricted Stock. 
 ARTICLE 10. DIVIDEND EQUIVALENTS 

Dividend Equivalents may be granted under the Plan to Employees and Consultants, either as a component of another Award or as a separate
Award, subject to such terms, conditions, restrictions and/or limitations as the Board may establish. In general, and subject to such terms, conditions, restrictions and/or limitations as the Board may establish, an Award of Dividend Equivalents
shall confer upon the Participant a right to receive, in the event of a cash or stock dividend or other distribution paid or made on the outstanding shares of Common Stock, an amount equal to the dividend or other distribution that would have been
received by the Participant had the shares of Common Stock covered by the Award been issued and outstanding on the record date established for such dividend or other distribution. Dividend Equivalents may be paid currently or may be deemed to be
reinvested in additional shares of Common Stock (which may thereafter accrue additional Dividend Equivalents). Any such reinvestment shall be at the Fair Market Value of the Common Stock at the time thereof. Dividend Equivalents may be paid in cash,
shares of Common Stock, other Awards or other property, or a combination thereof, in a single payment or in installments, and at such time or times as the Board shall determine. Dividend Equivalents granted as a component of another Award may
provide that such Dividend Equivalents shall be paid upon exercise, payment or settlement of or lapse of restrictions on such other Award, and that such Dividend Equivalents shall expire or be forfeited under the same conditions as such other Award.
Dividend Equivalents granted as a component of another Award may also contain terms and conditions different from such other Award. 

ARTICLE 11. OTHER INCENTIVE AWARDS 

Other Incentive Awards may be granted under the Plan to Employees based upon, payable in or otherwise related to, in whole or in part, whole
or fractional shares of Common Stock if the 

  
 -13- 

 
Board, in its sole discretion, determines that such Other Incentive Awards are consistent with the purposes of the Plan. Subject to the terms and provisions of the Plan, Other Incentive Awards
may be granted to Employees in such amount, upon such terms and at any time and from time to time as shall be determined by the Board. Each grant of an Other Incentive Award shall be evidenced by an Award Agreement that shall specify the amount of
the Other Incentive Award and the terms, conditions, restrictions and/or limitations applicable to such Award. Payment of Other Incentive Awards shall be made at such times and in such form, which may be cash, whole or fractional shares of Common
Stock or other property (or a combination thereof), as established by the Board, subject to the terms of the Plan. In the event payment is required in order to receive Common Stock pursuant to an Other Incentive Award, then the purchase price per
share shall not be less than: 
 (a) in the case of any Participant who owns stock possessing 10% or less of the total
combined voting power or value of all classes of stock of Oncologic or an Affiliate, 85% of the Fair Market Value per share of Common Stock at the time of the Award or at the time the purchase is consummated; and 

(b) in the case of any Participant who owns stock possessing more than 10% of the total combined voting power or value of all
classes of stock of Oncologic or an Affiliate, 100% of the Fair Market Value per share of Common Stock either at the time of the Award or at the time the purchase is consummated. 

ARTICLE 12. CORPORATE TRANSACTIONS 

12.1 Definition of Corporate Transaction. A “Corporate Transaction” shall mean any of the following: 

(a) Oncologic shall consummate a reorganization, merger, consolidation or any other transaction, in any case, with respect to
which persons who were the shareholders of Oncologic immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, own equity interests representing at least fifty-one percent (51 %) of the total combined voting
power of Oncologic or the resulting reorganized, merged or consolidated entity, as applicable; or 
 (b) the sale, lease,
transfer or other disposition of all or substantially all of the assets of Oncologic (other than to one or more direct or indirect a wholly-owned subsidiaries of Oncologic). 

12.2 Effect on Outstanding Awards. In the event of a Corporate Transaction, the Board, acting in its sole discretion without the
consent or approval of any Participant, may act to effect one or more of the following alternatives, which may vary among individual Participants and which may vary among Awards held by any individual Participant: 

  
 -14- 

 (a) accelerate the vesting of and the time at which Awards then outstanding may
be exercised so that such Awards may be exercised in full (irrespective of whether such Awards are fully exercisable prior to the date of such Corporate Transaction) for a limited period of time on or before a specified date fixed by the Board
(which date may be before or after the date of such Corporate Transaction), after which specified date all unexercised Awards and all rights of Participants thereunder shall terminate; 

(b) require the mandatory surrender to Oncologic by selected Participants of some or all of the outstanding Awards held by such
Participants (irrespective of whether such Awards are fully exercisable prior to the date of such Corporate Transaction) as of a date specified by the Board (which date may be before or after the date of such Corporate Transaction), in which event
the Board shall thereupon cancel such Awards and Oncologic shall pay to each Participant an amount of cash per share equal to whichever of the following amounts is applicable: 

(i) the per share price offered to stockholders of Oncologic in the reorganization, merger, consolidation or other transaction
described in Section 12.1(a), less the applicable exercise price, if any, payable by the Participant pursuant to such Award; or 

(ii) if such Corporate Transaction occurs pursuant to a type of transaction described in Section 12.1(c), the Fair Market
Value per share of Common Stock subject to such Award, as determined by the Board as of the date determined by the Board to be the date of such transaction, less the applicable exercise price, if any, payable by the Participant pursuant to such
Award. 
 In the event that the consideration offered to stockholders of Oncologic in any Corporate Transaction consists of anything other
than cash, the Board shall determine the fair cash equivalent of the portion of the consideration offered which is other than cash. 

(c) make such adjustments to Awards then outstanding so that such Awards thereafter cover the number and class of shares of
stock or other securities or property (including, without limitation, cash) to which the Participant would have been entitled pursuant to the terms of the Corporate Transaction had the Participant been the holder of record of the number of shares of
Common Stock covered by such Award; or 
 (d) in the event of a Corporate Transaction in which the holders of
Oncologic’s Common Stock receive shares of stock in the acquiring entity (“Acquiror Stock”), convert Awards into Awards to acquire (or with respect to) shares of Acquiror Stock (“Substitute Awards”). Each Substitute Award
shall be exercisable on substantially the same terms and conditions contained in the applicable Award, and shall cover such number of shares of Acquiror Stock and have such exercise price 

  
 -15- 

 
and other terms as the Board shall, in its discretion, deem appropriate in order to approximate with the Substitute Award an economic equivalent to the applicable Award. 

In the event of Corporate Transaction, the Board may, but shall not be required to, take any such action set forth in Sections 12.2(a) through (d) above
or shall be permitted to allow any or all outstanding Awards to remain so outstanding in accordance with the terms and conditions of the related Award Agreement. 

ARTICLE 13. AMENDMENT AND TERMINATION 

The Board may at any time suspend, terminate, amend or modify the Plan, in whole or in part; provided, however, that no amendment or
modification of the Plan shall become effective without the approval of such amendment or modification by the stockholders of Oncologic if such amendment or modification (i) increases the maximum number of shares subject to the Plan (except as
provided in Section 6.2), (ii) changes the designation or class of persons eligible to receive Awards under the Plan, or (iii) counsel for Oncologic determines that such approval is otherwise required by or necessary to comply with
applicable law. The Plan shall terminate upon the earliest to occur of (i) the termination of the Plan by the Board; (ii) the expiration of the ten-year period commencing on the date the Plan is adopted by the Board, or (iii) the
expiration of the ten-year period commencing on the date the Plan is approved by the shareholders of Oncologic. Upon termination of the Plan, the terms and provisions of the Plan shall, notwithstanding such termination, continue to apply to Awards
granted prior to such termination. No suspension, termination, amendment or modification of the Plan shall adversely affect in any material way any Award previously granted under the Plan, without the consent of the Participant holding such Award.

 The Board may amend the terms of any outstanding Award granted pursuant to this Plan, but any amendment that would adversely affect the
Participant’s rights under an outstanding Award shall not be made without the written consent of the Participant. The Board may, with a Participant’s written consent, cancel any outstanding Award or accept any outstanding Award in exchange
for a new Award. 
 ARTICLE 14. MISCELLANEOUS 

14.1 Award Agreements. After the Board grants an Award under the Plan to a Participant, Oncologic and the Participant shall enter into
an Award Agreement setting forth the terms, conditions, restrictions and/or limitations applicable to the Award and such other matters as the Board may determine to be appropriate. The terms and provisions of the respective Award Agreements need not
be identical. All Award Agreements shall be subject to the provisions of the Plan. In the event of any conflict between an Award Agreement and the Plan, the terms of the Plan shall govern. 

  
 -16- 

 14.2 Additional Conditions. Notwithstanding anything in the Plan to the contrary:
(i) Oncologic may, if it shall determine it necessary or desirable for any reason, at the time of grant of any Award or the issuance of any shares of Common Stock pursuant to any Award, require the recipient of the Award or such shares of
Common Stock, as a condition to the receipt thereof, to deliver to Oncologic a written representation of present intention to acquire the Award or such shares of Common Stock for his or her own account for investment and not for distribution; and
(ii) if at any time Oncologic further determines, in its sole discretion, that the listing, registration or qualification (or any updating of any such document) of any Award or shares of Common Stock issuable pursuant thereto is necessary on
any securities exchange or market or under any federal or state securities or blue sky laws, or that the consent or approval of any governmental or regulatory body is necessary or desirable as a condition of, or in connection with, the grant of any
Award, the issuance of shares of Common Stock pursuant thereto or the removal of any restrictions imposed on such shares, such Award shall not be awarded or such shares of Common Stock shall not be issued or such restrictions shall not be removed,
as the case may be, in whole or in part, unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to Oncologic. 

14.3 Legends on Stock Certificates. Unless the shares of Common Stock issued pursuant to an Award shall have been registered under the
1933 Act, each certificate representing such shares shall have conspicuously stamped, printed or typed on the face or back thereof the following legend: 

THE ISSUANCE OF THE COMMON STOCK EVIDENCED BY THIS CERTIFICATE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR APPLICABLE STATE
SECURITIES LAWS AND SUCH COMMON STOCK MAY NOT BE SOLD OR OTHERWISE TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS FIRST REGISTERED THEREUNDER OR UNLESS ONCOLOGIC, INC. RECEIVES A WRITTEN OPINION OF COUNSEL, WHICH OPINION AND COUNSEL ARE ACCEPTABLE TO
ONCOLOGIC, INC., TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED. 
 14.4 Nonassignability. No Award granted under the Plan may
be sold, transferred, pledged, exchanged, hypothecated or otherwise disposed of, other than by will or pursuant to the applicable laws of descent and distribution. Further, no such Award shall be subject to execution, attachment or similar process.
Any attempted sale, transfer, pledge, exchange, hypothecation or other disposition of an Award not specifically permitted by the Plan or the Award Agreement shall be null and void and without effect. All Awards granted to a Participant under the
Plan shall be exercisable during his or her lifetime only by such Participant or, in the event of the Participant’s legal incapacity, by his or her guardian or legal representative. 

  
 -17- 

 14.5 Withholding Taxes. The Company shall be entitled to deduct from any payment made
under the Plan, regardless of the form of such payment, the amount of all applicable income and employment taxes required by law to be withheld with respect to such payment, may require the Participant to pay to the Company such withholding taxes
prior to and as a condition of the making of any payment or the issuance or delivery of any shares of Common Stock under the Plan and shall be entitled to deduct from any other compensation payable to the Participant any withholding obligations with
respect to Awards under the Plan. In accordance with any applicable administrative guidelines it establishes, the Board may allow a Participant to pay the amount of taxes required by law to be withheld from or with respect to an Award by
(i) withholding shares of Common Stock from any payment of Common Stock due as a result of such Award or (ii) permitting the Participant to deliver to the Company previously acquired shares of Common Stock, in each case having a Fair
Market Value equal to the amount of such required withholding taxes. No payment shall be made and no shares of Common Stock shall be issued pursuant to any Award unless and until the applicable tax withholding obligations have been satisfied. 

14.6 No Fractional Shares. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan or any Award granted
hereunder, and no payment or other adjustment shall be made in respect of any such fractional share. 
 14.7 Notices. All notices
required or permitted to be given or made under the Plan or any Award Agreement shall be in writing and shall be deemed to have been duly given or made if (i) delivered personally, (ii) transmitted by first class registered or certified
United States mail, postage prepaid, return receipt requested, (iii) sent by prepaid overnight courier service or (iv) sent by telecopy or facsimile transmission, answer back requested, to the person who is to receive it at the address
that such person has theretofore specified by written notice delivered in accordance herewith. Such notices shall be effective (i) if delivered personally or sent by courier service, upon actual receipt by the intended recipient, (ii) if
mailed, upon the earlier of five days after deposit in the mail or the date of delivery as shown by the return receipt therefor or (iii) if sent by telecopy or facsimile transmission, when the answer back is received. Oncologic or a Participant
may change, at any time and from time to time, by written notice to the other, the address that it or such Participant had theretofore specified for receiving notices. Until such address is changed in accordance herewith, notices hereunder or under
an Award Agreement shall be delivered or sent (i) to a Participant at his or her address as set forth in the records of the Company or (ii) to Oncologic at the principal executive offices of Oncologic clearly marked “Attention: LTIP
Administration.” 
 14.8 Binding Effect. The obligations of Oncologic under the Plan shall be binding upon any successor
corporation or organization resulting from the merger, consolidation or other reorganization of Oncologic. The terms and conditions of the Plan shall be binding upon each Participant and his or her heirs, legatees, distributees and legal
representatives. 

  
 -18- 

 14.9 Severability. If any provision of the Plan or any Award Agreement is held to be
illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining provisions of the Plan or such agreement, as the case may be, but such provision shall be fully severable and the Plan or such agreement, as the case may
be, shall be construed and enforced as if the illegal or invalid provision had never been included herein or therein. 
 14.10 No
Restriction of Corporate Action. Nothing contained in the Plan shall be construed to prevent Oncologic or any Affiliate from taking any corporate action (including any corporate action to suspend, terminate, amend or modify the Plan) that is
deemed by Oncologic or such Affiliate to be appropriate or in its best interest, whether or not such action would have an adverse effect on the Plan or any Awards made or to be made under the Plan. No Participant or other person shall have any claim
against Oncologic or any Affiliate as a result of such action. 
 14.11 Governing Law. The Plan shall be governed by and construed in
accordance with the internal laws (and not the principles relating to conflicts of laws) of the State of California, except as superseded by applicable federal law. 

14.12 No Right, Title or Interest in Company Assets. No Participant shall have any rights as a stockholder of Oncologic as a result of
participation in the Plan until the date of issuance of a stock certificate in his or her name and, in the case of Restricted Stock, unless and until such rights are granted to the Participant under the Plan. To the extent any person acquires a
right to receive payments from the Company under the Plan, such rights shall be no greater than the rights of an unsecured creditor of the Company, and such person shall not have any rights in or against any specific assets of the Company. All of
the Awards granted under the Plan shall be unfunded. 
 14.13 Risk of Participation. Nothing contained in the Plan shall be construed
either as a guarantee by Oncologic or its Affiliates, or their respective stockholders, directors, officers or employees, of the value of any assets of the Plan or as an agreement by Oncologic or its Affiliates, or their respective stockholders,
directors, officers or employees, to indemnify anyone for any losses, damages, costs or expenses resulting from participation in the Plan. 

14.14 No Guarantee of Tax Consequences. No person connected with the Plan in any capacity, including, but not limited to, Oncologic and
the Affiliates and their respective directors, officers, agents and employees, makes any representation, commitment or guarantee that any tax treatment, including, but not limited to, federal, state and local income, estate and gift tax treatment,
will be applicable with respect to any Awards or payments thereunder made to or for the benefit of a Participant under the Plan or that such tax treatment will apply to or be available to a Participant on account of participation in the Plan. 

14.15 Continued Employment or Service. Nothing contained in the Plan or in any Award Agreement shall confer upon any Participant the
right to continue in the employ or service of the Company, or interfere in any way with the rights of the Company to terminate a Participant’s employment or service at any time, with or without cause. 

14.16 Financial Reports. Oncologic shall deliver, at least annually, its financial statements to each Participant, unless such
Participant is a key employee whose duties in connection with the Company assure such Participant access to equivalent information. 

14.17 Miscellaneous. Headings are given to the articles and sections of the Plan solely as a convenience to facilitate reference. Such
headings shall not be deemed in any way material or relevant to the construction of the Plan or any provisions hereof. The use of the masculine gender shall also include within its meaning the feminine. Wherever the context of the Plan dictates, the
use of the singular shall also include within its meaning the plural, and vice versa. 
 IN WITNESS WHEREOF, this Plan has been executed as
of this 9th day of December, 2000. 
  

					
	Oncologic, Inc.
		
	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

  
 -19-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]